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BACKGROUND: In the United States, chronic hepatitis C virus (HCV) infection afflicts 
approximately 3.2 million persons and is the leading indication of liver transplantation. 
Therapies for chronic HCV are not completely effective and African Americans are significantly 
less responsive to therapy than Caucasian Americans. Studies suggest that lipoproteins and 
cholesterol metabolism play a role in biological mechanisms of the HCV life cycle. This 
dissertation characterizes the serum lipid profile in a cohort with genotype 1 chronic HCV 
infection, the predominant HCV genotype in the United States. STUDY POPULATION: 
Participants for this study were from the Virahep-C study, a prospective study of resistance to 
antiviral therapy involving 401 treatment naïve people with chronic hepatitis C (genotype 1) 
infection who underwent combination pegylated interferon alfa-2a + ribavirin therapy for up to 
48 weeks. Included in this dissertation analysis were 330 participants who had serum lipid 
profile data before starting therapy. RESULTS: Before treatment, HCV viral level was directly 
associated with triglyceride levels, liver fat was directly and inversely related to triglycerides and 
high density lipoprotein cholesterol, respectively, and severe fibrosis was associated with lower 
of total and high density lipoprotein cholesterol levels. Over the course of therapy, all lipid 
profile measures changed during 6 months of treatment, and post-treatment, changes were 
limited to 6 month virological responders. For some lipid profile measures, changes during 6 
months of treatment differed by race and were related to the amount of interferon taken. Lastly, 
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components of the lipid profile were significant predictors of sustained virological response in 
univariable and multivariable analyses. CONCLUSIONS: This dissertation highlights the 
importance of the lipid profile in relation to aspects of liver disease, potential mechanisms of 
HCV eradication attributed to antiviral therapy, and virological response to therapy. The findings 
are of public health significance as they may highlight opportunities for new therapeutic targets 
and intervention studies to improve virological response, as well as elucidate factors involved in 
the racial disparity in treatment efficacy.  
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PREFACE 
This dissertation project afforded me the unique opportunity to examine the relevance of the lipid 
profile to chronic HCV infection, a new area of focus in HCV research. The implementation of 
the three projects has been a rewarding experience and has stimulated more questions than 
answers, which may guide further studies. To my committee, thank you for your guidance and 
mentoring throughout this process. I have learned a great deal about epidemiology and am 
grateful for the outstanding training that I have received here in the Department of 
Epidemiology. To my family, friends, and especially my wife, without your support none of this 
would have been possible.    
 
 
 
1.0  GENERAL BACKGROUND 
1.1 THE HEPATITIS C VIRUS 
1.1.1 Epidemiology  
The hepatitis C virus (HCV) is a viral capsid-enclosed RNA virus of the Flaviviridae family in 
the Hepacivirus genus.1 Six genotypes comprise HCV with varying predominance according to 
geography: genotype 1 predominates in the United States (US) and Northern Europe; genotype 2 
in the Mediterranean region and the Far East; genotype 3 in Europe; genotypes 4a and 5a in 
South Africa; and genotype 6 in Hong Kong, Vietnam, and Australia.2 The US prevalence of 
HCV in the non-institutionalized population is an estimated 1.6% (4.1 million persons) for HCV 
exposure, and 1.3% (3.2 million persons) for chronic infection.3 A report from US correctional 
facilities suggests that the prevalence of HCV infection may be as high as 29% to 43% in 
institutionalized inmate populations.4  
In the US, the primary mode of HCV transmission is parenteral and the main risk factors 
include injection drug use or receipt of a blood transfusion prior to 1991, the year when HCV 
screening of the blood supply was implemented. Although sexual intercourse and vertical 
transmission are other means of transmission, HCV transmission by these modes is believed to 
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be rare. Other risk factors of infection include exposure to contaminated blood products, needle-
stick among health care workers, and tattooing.5  
After initial exposure to HCV, the disease course varies and 55% to 85% develop chronic 
infection.1 Factors associated with higher rates of HCV chronicity include younger age at 
infection, male gender, African American (AA) race, lack of a jaundice reaction early in the 
infection, and immune deficiency. During the early course of infection, levels of the liver 
enzyme alanine aminotransferase (ALT) initially increase, then decline and fluctuate thereafter.6 
Among chronically active HCV infected people, the disease course may progress with liver 
damage leading to cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC).5 Aside 
from irregular fatigue, the majority of people with chronic hepatitis C infection are 
asymptomatic.7  
1.1.2 Treatment  
The current standard antiviral regimen for chronic HCV consists of combination pegylated 
interferon (PEG-IFN) alfa-2a and ribavirin for up to 48 weeks.8 Antiviral therapy has several 
common side-effects, including anemia, neutropenia, fatigue, headache, pyrexia, myalgia, rigors, 
insomnia, nausea, alopecia, irritability, arthralgia, anorexia, dermatitis, and depression.9 
Management strategies for side-effects include dose reductions of ribavirin and PEG-IFN and in 
some cases treatment discontinuation is necessary.9  
The efficacy of therapy differs by genotype. Rates of sustained viral response (SVR), 
defined as undetectable levels of HCV RNA 24 weeks after treatment cessation, are higher for 
genotypes 2, 3, and 4 (76% to 77%) than genotype 1 (46%).8 A racial disparity in treatment 
efficacy exists in genotype 1 infected populations with AAs having lower rates of SVR (19% to 
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28%) compared to Caucasian Americans (CAs) (39% to 52%).10-12 Factors that explain the racial 
difference in efficacy are unknown.10  
1.1.3 Chronic HCV infection and liver disease  
Chronic HCV infection is involved in the progression of specific forms of liver disease by the 
host immune response activation against hepatocellular tissue.6 Although highly variable, the 
general sequelae of liver damage is hepatic inflammation, followed by either scar tissue 
formation (referred to as hepatic fibrosis) or lipid droplet accumulation (referred to as fatty liver 
disease, steatosis, or hepatosteatosis) which may lead to liver cirrhosis, end-stage liver disease, 
and an increased risk of HCC. Host etiological factors unrelated to HCV infection may be 
involved in liver disease and include poor nutrient intake, medication, alcohol consumption, and 
diabetes. Fibrosis and steatosis may precede chronic HCV infection, suggesting liver disease 
progression due to host etiology, or occur with chronic infection, indicating the involvement of 
HCV as a contributing or causative agent of liver disease. Hepatic iron deposition and iron 
overload also occur among individuals with chronic HCV infection have been associated with 
poor prognosis for treatment efficacy and liver disease progression; however, the biological role 
of serum iron and iron deposition remains unclear in the context of HCV infection.13-15   
1.1.4 Liver disease measures  
Noninvasive non-biopsy methods of assessing fibrosis and steatosis using ultrasound 
imaging techniques are available and are generally adequate to detect fibrosis and moderate to 
severe steatosis.16-18 However, to quantify the extent of liver damage, percutaneous liver biopsy 
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is considered to be the gold standard. The Histological Activity Index (HAI) scoring system, also 
known as the Knodell score, was proposed in 1981 to provide a consistent and clinically 
validated measure with high intraobserver and interobserver agreement.19 Since its inception, the 
HAI scoring system has been modified to include of four aspects of liver disease: periportal 
bridging; intralobular degeneration and focal necrosis; portal inflammation; and fibrosis. 
Compared to the original HAI, the Modified HAI system includes additional scoring criteria 
within each aspect of liver disease. Excluding the fibrosis score, the modified HAI scores are 
summed to create an overall measure of hepatic inflammation, also known as the Ishak 
necroinflammatory score.20 Another scoring system is the METAVIR scale, which assesses the 
same aspects of liver disease as the Modified HAI system, though using different criteria.21 In 
both the Modified HAI and METAVIR scales, cirrhosis is defined by higher scores within the 
fibrosis assessment. Within individuals with cirrhosis, hepatic function is graded by the Child-
Pugh score (or the Child-Pugh-Turcotte modification) comprised of five non-biopsy measures, 
including total bilirubin, serum albumin, coagulopathy, ascites, and hepatic encephalopathy.22 
The percent fat involvement of hepatocytes assessed by liver biopsy interpretation is used to 
define steatosis and assign a fat score. Finally, an iron score ranging from 0 to 4 is assigned 
according to the amount of iron deposition in hepatocellular tissue.22  
 
1.1.5 Public health implications of chronic HCV 
In the US, chronic HCV infection-mediated end-stage liver disease has been implicated in the 
majority of adult liver transplants.23 The estimated annual direct health care cost of HCV, 
including liver transplantation, is an estimated $1.8 billion and a 4-fold increase in the number of 
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persons with chronic HCV infections is projected to occur between 1990 and 2015.24, 25 These 
statistics underscore the significant burden to the US health care system that is associated with 
chronic HCV infection.  
Treatments to successfully cure the disease may not only halt or reverse the progression 
of liver disease caused by chronic HCV infection, but also reduce the potential for transmission.5  
From a public health perspective, primary prevention strategies to reduce the spread of infection 
include maintaining an adequately screened blood supply, using sterile percutaneous instruments 
for medical procedures or tattooing, and needle exchange programs for injection drug user 
populations. In addition, provision of substance abuse treatment for those with addiction may be 
another primary prevention strategy to reduce new exposures to HCV through injection drug use. 
For those with undiagnosed chronic HCV infection, targeted screening of at risk populations is a 
secondary prevention strategy. Screening programs may target high risk populations for HCV, 
such as inmate populations, which have been shown to have rates of HCV exposure varying 
between 29% to 43%.4 Tertiary prevention strategies for chronic HCV currently include 
combination antiviral therapy, the efficacy of which varies depending on genotype, and 
demographic characteristics, such as gender and race.8, 10-12 In HCV genotype 1, lower rates of 
virological response to treatment among AAs compared to CAs may also impact tertiary 
prevention approaches. Given the lower chance of treatment response, infected AA individuals 
may be less willing to undergo antiviral therapy than CAs.  
More effective treatment approaches to chronic HCV may not only reduce the health care 
costs associated with antiviral therapy, allowing resources to be refocused on other public health 
problems, but also eradicate this chronic infectious disease from the human blood reservoir, 
reducing the potential for transmission. Moreover, effective treatment carries the potential to 
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improve the health-related quality of life for those with chronic HCV infection, which has been 
shown to  improve among those who respond to treatment.26 Thus, the public health implications 
of chronic HCV are significant and research to improve treatment approaches, as well as reduce 
transmission of infection is warranted.   
1.2 THE LIPID PROFILE  
1.2.1 Components and metabolic pathways  
Serum lipoproteins are classified according to size, density, and apolipoprotein composition. By 
increasing size and decreasing density, lipoprotein classes consist of high density lipoprotein 
(HDL), low density lipoprotein (LDL), intermediate density lipoprotein (IDL), very low density 
lipoprotein (VLDL), and chylomicrons. The density of each lipoprotein is primarily dictated by 
the amount of triglyceride (TG), a high energy store. Whereas HDL is associated with the 
structural proteins apolipoprotein A-I and A-II, apolipoprotein B-100 comprises VLDL, IDL, 
LDL, and apolipoprotein B-48 is the construct of chylomicrons. Cardiovascular disease (CVD) 
risk is inversely associated with serum concentrations of HDL-cholesterol (HDLc), and directly 
related to VLDL-cholesterol (VLDLc), LDL-cholesterol (LDLc), total cholesterol (TC), and 
TG.27  
Lipoprotein metabolism includes both exogenous and endogenous pathways. In the 
exogenous pathway, dietary fat enters the serum from the small intestine in the form of 
chylomicrons comprised of large amounts of TG. Lipoprotein lipase removes TG for energy or 
storage and chylomicron remnants are removed from the serum by the liver. Cholesterol from 
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chylomicron remnants is extracted for further metabolism, incorporation into cellular 
membranes, or excretion in bile into the intestinal tract. The endogenous pathway involves 
hepatic TG secretion from the liver into the serum as TG rich VLDL particles. Similar to the 
exogenous pathway, the lipoprotein lipase enzyme removes TG for energy metabolism, 
modifying VLDL particles to IDL and LDL. Cholesterol is then either returned to the liver via 
LDL binding to the LDL receptor or is brought to peripheral tissue for incorporation into cellular 
membranes. In the serum, LDL may bind and deposit cholesterol, including within arterial walls, 
promoting atherosclerosis through the development of plaque.6 In a reverse process, HDL 
removes cholesterol from the periphery and is taken up by the liver via scavenger receptor-
mediated entry. Excess cholesterol may be excreted from the liver into the digestive tract as 
bile.27  
1.2.2 Methods of assessment  
Although there are numerous methods to assess lipid profile concentrations, the standard 
approach is to estimate TC, TG, and HDLc by direct methods and to calculate LDLc indirectly 
using the Friedewald equation when TG is less than 400 mg/dL (LDLc = TC – VLDLc  – HDLc) 
where VLDLc = TG / 5.27, 28  When TG is at least 400 mg/dL, LDLc is estimated by direct 
methods. Reference samples (e.g., from the Centers for Disease Control and Prevention (CDC)) 
are used in laboratories that conduct routine lipid profile analyses for quality assessment and 
control purposes.27  
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2.0  INTRODUCTION  
2.1 BIOLOGICAL MECHANISMS OF THE HCV LIFE CYCLE 
Two major biological mechanism themes are apparent from in vitro and animal model studies: a 
mechanism of receptor mediated HCV entry from the serum into hepatocytes and the reliance on 
cholesterol and lipoprotein metabolic pathways for HCV replication and secretion. However, 
findings from non-epidemiologic data are varied and often contradictory, which may be 
attributed to the numerous HCV experimental particles and tissue systems used to simulate HCV 
infectivity.29   
2.1.1 HCV receptor-mediated entry into hepatocytes 
Studies suggest an association of HCV with lipoproteins in the serum in the form of lipoprotein-
virus conglomerate (LVC) particles consisting of chylomicrons, VLDL, LDL, TG, and 
apolipoproteins B and E.30, 31 Electron microscopy work further indicates that HCV capsids 
reside within the core of the LVC particle, a possible means of being masked from the host 
immune response.30 Other work suggests that HCV may bind in a more specific manner with 
lipoproteins to form lipoprotein-viral particles with LDL and VLDL, LDL, or HDL.32, 33 Various 
receptors involved in lipoprotein-viral particle entry into hepatocytes have been proposed, 
including the scavenger receptor B1 (SR-B1) and LDL receptor.34-37 The LDL receptor 
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mechanism of entry, however, is controversial.38, 39 Direct entry of free HCV (not associated with 
lipoproteins) may also occur through binding with SR-B1 or CD81.40-42  
2.1.2 HCV replication and secretion 
Based on in vitro work, HCV replication has been proposed to occur at the hepatocyte 
endoplasmic reticulum (ER), dependent on cholesterol metabolism.29, 43-46 HCV secretion from 
the hepatocyte into the serum may also involve the metabolic pathway of VLDL resulting in the 
secretion of VLDL-HCV complexed particles. In contrast, other work using transgenic mouse 
models suggests that VLDL secretion may be disrupted by an interaction of HCV core with 
microsomal triglyceride transfer protein inhibiting viral secretion and resulting in intrahepatic 
TG accumulation, a possible mechanism of HCV-induced steatosis.46 Reasons for different 
proposed mechanisms of HCV secretion from in vitro and animal studies are unclear.   
2.2 LITERATURE REVIEW OF EPIDEMIOLOGIC STUDIES: CHRONIC HCV 
INFECTION, LIVER DISEASE, AND THE LIPID PROFILE  
Compared to non-HCV infected control participants, studies have shown that those with chronic 
HCV infection tend to have lower TC, LDLc, HDLc, or TG levels 47-50, although one study found 
higher TG levels.51 These findings suggest that there may be an association between chronic 
HCV infection and CVD risk. Comparing lipid profile measures, Marzouk et al. suggested that a 
“favorable” CVD risk profile is associated with chronic HCV infection based on findings of 
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significantly lower LDLc and TG levels in chronically infected people versus a non-HCV 
exposed group.48  
The impact of antiviral HCV therapy on the lipid profile has also been investigated. A 
study of people treated with non-PEG-IFN found increasing TC and TG during antiviral 
therapy.52 Post-therapy, TC levels continued to increase whereas TG returned to pre-treatment 
levels. Another study found that during mono- or combination therapy of either non-PEG-IFN or 
PEG-IFN, TG levels increased, though TC levels remained the same.53 Changes in the lipid 
profile during antiviral therapy may differ according to HCV genotype. One study found 
significant increases in TC during and after therapy compared to baseline in a subgroup with 
HCV genotype 3, but not genotype 1, with post-treatment increases in TC only observed among 
genotype 3 sustained virological responders.54 TG levels have been reported to increase during 
therapy in an exclusively genotype 1 infected cohort.53  
The lipid profile in both HCV infected and non-infected cohorts has been associated with 
liver disease measures including steatosis and fibrosis.55-58 In a non-HCV exposed group of 
people, TG and HDLc were directly and inversely related to steatosis, respectively.55 TC and 
LDLc have been reported to be inversely related to steatosis and fibrosis when assessed in 
groups with chronic HCV infection.56, 57 TG levels have also been associated with steatosis, 
although inversely in one report among genotype 3 and non-genotype 1 groups 57, and directly in 
a genotype 1 cohort 58. The genotype specific manner of the relationship between TG and 
steatosis is consistent with the notion that genotype 3 steatosis is a viral-mediated process, 
whereas genotype 1 is an indirect consequence of metabolic changes, such as insulin resistance, 
that occur due to infection.59, 60   
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Lastly, a growing body of recent evidence suggests that baseline serum lipid profile 
measures may be important prognostic factors of treatment efficacy of combination antiviral 
therapy. Several studies suggest that high pretreatment LDLc and TC levels are associated with 
higher rates of treatment response in multivariable analyses.61-65 Other work revealed higher 
baseline TG levels among sustained viral responders compared to non-responders, though 
baseline TC did not differ significantly between the two response groups.52 
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3.0  THREE PROPOSED DISSERTATION PROJECTS 
3.1.1 Specific aims: project 1 
Assess whether demographic, clinical, and liver disease severity (histological, biochemical, and 
virological) measures are associated with the lipid profile among treatment naïve participants 
with chronic HCV infection, genotype 1.   
3.1.2 Specific aims: project 2 
Evaluate changes between baseline and on- and post-treatment lipid profile measures. Assess 
whether baseline demographic, clinical, and liver disease measures (histological, biochemical, 
and virological) are associated with changes in lipid profile measures over the course of antiviral 
therapy.   
3.1.3 Specific aims: project 3 
Assess whether baseline measures of lipid profile and changes in lipid fractions during therapy 
are predictors of treatment efficacy. If lipid profile measures are significant predictors of 
treatment response, determine if multivariable models including lipid profile measures are more 
predictive of treatment efficacy compared to other multivariable assessments not including lipid 
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profile measures. Assess if lipid fraction measures explain any of the racial disparity in treatment 
efficacy.  
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4.0  THE VIRAHEP-C STUDY 
The Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) was a 
National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) funded project which enrolled participants between September 2002 and 
January 2004. Details of the Virahep-C study are described elsewhere.10 In brief, the Virahep-C 
study was a multicenter treatment trial which included 196 AA and 205 CA participants to 
investigate the clinical, immunological, virologic, and host genetic factors that contribute to 
antiviral treatment efficacy, particularly racial differences. Treatment naïve participants between 
the ages of 18 and 70 years with chronic infection of hepatitis C virus (genotype 1) received 
combination therapy consisting of peginterferon alfa-2a and ribavirin for up to 48 weeks. 
Participants were to have undergone liver biopsy evaluations within 18 months prior to the 
screening evaluation and all biopsies were scored by a single hepatopathologist. There were 
several exclusion criteria including positive HIV or HBV status, consumption of more than 2 
alcoholic drinks per day, evidence of alcohol or drug abuse, indication of anemia, 
decompensated liver disease, other chronic liver diseases, and inability or unwillingness to grant 
informed consent.   
Funding for lipid profile analyses utilizing stored fasting serum samples was obtained for 
an ancillary study examining the relationships between host genetic polymorphisms, the lipid 
profile, and steatosis (KL2 RR024154-02 to LJY). Of the 401 participants enrolled in Virahep-C, 
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lipid profile analyses were conducted among participants who provided genetic consent (n=374) 
and had available stored fasting serum samples at baseline (n=335). Five participants who 
reported use of lipid lowering agents at the screening evaluation were excluded from statistical 
analyses. Thus, the sample for this dissertation analysis included 330 participants (160 AA and 
170 CA).  
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5.0  PROJECT 1: THE SERUM LIPID PROFILE AND ASSOCIATIONS WITH 
LIVER DISEASE AND VIRAL LEVELS IN A TREATMENT NAÏVE CHRONIC 
HEPATITIS C INFECTED COHORT 
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5.1 ABSTRACT 
BACKGROUND: Findings from in vitro and transgenic animal studies suggest mechanisms of 
hepatitis C virus (HCV) entry into hepatocytes via lipoprotein receptors, viral replication related 
to cholesterol metabolism, secretion from hepatocytes into the serum as HCV complexed with 
very low density lipoprotein (VLDL), and HCV-induced steatosis. Epidemiological studies of 
chronic HCV infection have shown that steatosis and fibrosis are inversely associated with total 
cholesterol (TC) and low density lipoprotein cholesterol (LDLc). Steatosis and fibrosis have also 
been associated with triglyceride (TG) levels, though the direction of the relationship is 
inconsistent across studies. AIM: To assess whether HCV viral level and histological factors are 
associated with the serum lipid profile in a treatment naïve cohort with chronic HCV genotype 1 
infection. METHODS: Participants were from the Study of Viral Resistance to Antiviral 
Therapy (Virahep-C), a prospective study of treatment naïve participants who received 
combination therapy of PEG-IFN alfa-2a + ribavirin for up to 48 weeks. Pretreatment fasting 
lipid profiles, processed at a central lab, were analyzed for 160 African Americans and 170 
Caucasian Americans. Liver biopsies were assessed for steatosis, histological inflammation, 
fibrosis, and iron deposition. Linear regression was used to evaluate associations of each lipid 
profile measure with serum HCV level and liver disease measures. Variables were transformed 
as appropriate to meet model assumptions. RESULTS: Adjusting for race and age, there was a 
significant direct relationship between TG and serum HCV level. Participants with steatosis had 
higher TG levels than those without steatosis. High density lipoprotein cholesterol (HDLc), 
LDLc, and TC levels were significantly lower for participants with severe fibrosis than those 
without this histological feature. In contrast to HDLc, LDLc, and TC, which were inversely 
related to serum ferritin, TG levels were directly related to this iron status measure. Iron status 
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and saturation measures were also associated biopsy-assessed liver disease. CONCLUSIONS: 
In participants with HCV genotype 1 infection, more severe liver disease was associated with 
lower lipid profile levels, with the exception of TG levels which were directly related to 
steatosis. The direct relationship between HCV RNA level and TG levels is consistent with 
proposed mechanisms of VLDL/HCV particle secretion. In contrast, the direct relationship 
between TG level and steatosis is inconsistent with posited mechanisms of HCV-induced 
steatosis, a possible reflection of HCV genotype 1 infection and a metabolic etiology of steatosis. 
Although serum ferritin was associated with the lipid profile and liver disease, its biological 
relevance is unclear. Further investigation is warranted to clarify the role of the lipid profile in 
the context of chronic HCV infection.  
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5.2 INTRODUCTION 
In the United States, approximately 4.1 million non-institutionalized people are infected with 
HCV, 3.2 million of whom are chronically infected.3 A potential 4-fold increase in number of 
persons with chronic HCV infection is projected to occur between 1990 and 2015.24 The 
estimated direct health care cost of HCV in 1997, including liver transplantation for which 
chronic HCV ranks as the leading indication in the US, was an estimated $1.8 billion.23, 25 These 
statistics underscore the significant public health burden of chronic HCV infection.  
Recent reports suggest that the serum lipid profile may be relevant to HCV and its life 
cycle. Compared to groups of people without HCV infection, several studies have associated 
chronic HCV with lower total cholesterol (TC), low density lipoprotein cholesterol (LDLc), and 
high density lipoprotein cholesterol (HDLc) levels.47-50 Triglyceride (TG) levels have also been 
shown to be associated with HCV infection with reports of both lower 47-50 and higher levels51, 
the direction of the relationship possibly reflecting different contributions of host factors to TG 
levels.    
The lipid profile in both non-infected and HCV-infected cohorts have been shown to be 
associated with liver disease measures, including steatosis and fibrosis.55-58 In a non-HCV 
exposed population, TG and HDLc were directly and inversely related to steatosis, respectively, 
and no significant association was found with LDLc.55 Among chronic HCV infected cohorts, 
inverse relationships with TC and LDLc with steatosis and fibrosis have been reported.56, 57 
Triglyceride levels have also been shown to be associated with steatosis, although inversely in 
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one report 57, and directly in another58, with the direction of the relationship differing by HCV 
genotype 3 and 1, respectively.  
Findings from in vitro work support a mechanism involving HCV/lipoprotein complexes 
and LDL receptor or scavenger receptor-B1 (SR-B1) meditated HCV entry into hepatocytes.34-37 
However, the LDL receptor mediated mechanism is controversial.38, 39 Entry of free HCV (not in 
association with lipoproteins) may also occur through binding with SR-B1 or CD81.40-42 Other 
work posits a process of HCV viral particle assembly and secretion related to VLDL metabolic 
pathways.29, 43-46 In addition, the interaction of the HCV core with microsomal triglyceride 
transfer protein (MTP) has been shown to disrupt VLDL secretion resulting in intrahepatic TG 
accumulation, a possible mechanism of HCV-induced steatosis.46 
The lipid profile and liver disease may also be related to serum iron measures. In a non-
HCV exposed group of people, elevated serum ferritin was associated with significantly lower 
HDLc and higher TG levels.66 In addition, in an assessment of an exclusively HCV infected 
cohort, serum ferritin was found to be directly related to liver fat.14 Chronic HCV infection has 
been associated with elevated ferritin levels compared to non-exposed groups, a possible 
reflection of HCV infection or HCV-induced liver disease.67-69 These findings suggest that a 
relationship may exist between serum iron measures, liver disease, the lipid profile, and possibly 
HCV infection, although the biological mechanism is unclear.    
The modifications the lipid profile associated with HCV infection may influence 
cardiovascular disease (CVD) risk, although several other factors may play a role. Compared to 
non-HCV exposed groups, results across the few studies that have assessed CVD risk are 
inconsistent.48, 49, 51 Whereas one study suggests that CVD risk may be lower in association with 
chronic HCV based on comparisons of lipid profile measures,48 other work suggests no 
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difference in risk based on arteriolsclerotic measures,49 and yet another found higher 
atherosclerotic risk.51  The different study findings may be attributed to the different study 
populations, measures of CVD used, or a combination of these study characteristics.  
The relationship between the serum lipid profile, liver disease, and possible HCV entry, 
replication, and secretion processes is complex. This study characterizes factors associated with 
the serum lipid profile in a treatment naïve cohort with chronic HCV infection, genotype 1. 
Within an epidemiologic context, these findings reflect reports from in vitro and animal studies 
of potential pathogenic mechanisms of HCV-induced liver damage, as well as mechanisms of 
HCV entry into hepatocytes from the serum, replication, and secretion.  In addition, this study 
also examines the associations between serum iron measures, liver disease, and lipid profile 
measures, and assesses factors associated with dyslipidemia.  
5.3 METHODS 
5.3.1 Study population 
Participants were drawn from The Study of Viral Resistance to Antiviral Therapy of Chronic 
Hepatitis C (Virahep-C) cohort, which is described elsewhere.10 In brief, the Virahep-C study 
included 196 AA and 205 CA participants to investigate the clinical, immunological, virologic, 
and host genetic factors that contribute to the racial disparity in antiviral treatment efficacy. 
Participants between the ages of 18 and 70 years with chronic HCV (genotype 1) infection were 
enrolled and underwent combination therapy consisting of PEG-IFN alfa-2a and ribavirin for up 
to 48 weeks. Funding for additional lipid profile analyses utilizing stored serum samples was 
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obtained for an ancillary study of the pathogenesis of steatosis and insulin resistance in chronic 
HCV infection (KL2 RR024154-02 to LJY). Lipid profile analyses were conducted among 
participants who provided genetic consent (n=374) and had available stored fasting serum 
samples at baseline (n=335). Five participants who reported use of lipid lowering agents at the 
screening evaluation were excluded from the statistical analysis. The final sample included in 
this analysis consisted of 330 participants (160 AA and 170 CA).  
 
5.3.2 Study measures 
Estimates of the lipid profile fractions, TG, LDLc, HDLc, and TC were obtained through 
analysis of stored fasting serum samples at the Heinz Nutrition Laboratory in the Department of 
Epidemiology, University of Pittsburgh. If TG levels were less than 400 mg/dL, the Friedewald 
formula was used to calculate LDLc indirectly (LDLc = TC − HDLc − 0.20 X TG).28 Samples 
for which TG levels were at least 400 mg/dL (n=3) had LDLc assessed directly. Dyslipidemia 
was defined using the cutoffs from the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP) III recommendations as any of the following: LDLc greater than or equal 
to 130 mg/dL, HDLc less than 40 mg/dL, TC greater than or equal to 200 mg/dL, or TG greater 
than or equal to 150 mg/dL.70  
Biopsy-assessed liver disease measures included fibrosis, fat score, inflammation, and 
iron score. Inflammation and fibrosis were assessed using the criteria of the Histological Activity 
Index (HAI) by a single hepatopathologist.19, 20 An Ishak fibrosis score of at least 3 was 
classified as severe fibrosis and steatosis was defined as a fat score of greater than zero 
representing at least 5% fat involvement of hepatic tissue. An iron score of 0, 1, or 2 was 
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assigned according to the amount of iron deposits in hepatic tissue. Summing non-Ishak fibrosis 
scores from the HAI, a total HAI inflammation score was calculated. HAI inflammation scores 
between 0 and 6 were classified as mild, 7-11 as moderate, and 12 or greater as severe 
inflammation. Total HAI inflammation, Ishak fibrosis, and fat scores were also analyzed. Other 
non-biopsy serologic liver disease indicators included alanine and aspartate aminotransferase 
(ALT and AST, respectively), alkaline phosphatase, total bilirubin, the international normalized 
ratio (INR), white blood cell count (WBC), platelet count, serum ferritin (an iron status 
measure), and the percent iron/total iron binding capacity (TIBC) (an iron saturation measure).  
5.3.3 Statistical analysis 
Categorical measures were summarized as frequency and percent with differences across 
nominally classified groups (i.e., race, gender, health insurance status, employment status, 
smoking status, alcohol consumption of at least 2 drinks per week, history of diabetes and 
hypertension, HCV genotype, and severe fibrosis) assessed using a Pearson’s chi-square test or 
the exact equivalent. Differences in categorical measures across ordinal groups (i.e., educational 
attainment and iron scores), were assessed using a Jonckeere-Terpstra test, or the exact 
equivalent. Continuous measures were summarized as medians and interquartile ranges with 
differences in group distributions assessed using a Wilcoxon rank sum test (for comparison of 
two groups) or a Kruskal-Wallis test (for comparison of more than two groups). To assess the 
trend of distributions in lipid profile measures across ordinal fat score categories, test of trend 
was assessed using linear regression with lipid profile measures as the dependent variables. For 
all statistical tests, a p-value of <0.05 was considered statistically significant.  
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Since the dichotomous outcome of dyslipidemia was common, a relative risk model with 
a robust variance estimator was used.71 Linear regression was employed to model each lipid 
profile measure as a continuous outcome. In regression models, TG, HDLc, and TC were 
transformed to the natural logarithm (ln) scale to achieve normality. Predictors were transformed 
to make associations with lipid profile measures linear and also centered about their means. In 
multivariable analyses, a stepwise selection approach was used for variable reduction. All 
analyses were conducted using Statistical Analysis Software (SAS) Version 9 (Carey, NC) or 
STATA Version 9 (College Station, TX).  
5.4 RESULTS 
Characteristics of the study cohort are summarized by race. (Tables 5-1 and 5-2) AAs did not 
significantly differ from CAs by age, gender, employment status, health risk behaviors (smoking 
status and weekly alcohol consumption), HCV level, AST, INR, WBC count, platelet count, 
percent Iron/TIBC, Ishak fibrosis, total HAI score, steatosis, TG, HDLc, and TC (p>0.05 for all). 
Compared to CAs, a larger percentage of AAs had any form of health insurance coverage, public 
health insurance, less education, a history of diabetes or hypertension, and HCV sub-genotype 1b 
(p<0.05 for all). As a group, AAs had higher body mass indices (BMIs), higher alkaline 
phosphatase, and ferritin levels, and lower ALT, total bilirubin, albumin, and LDLc levels than 
CAs (p<0.05 for all). Several significant racial differences were noted among females, but not 
males, with AA females having higher BMIs, waist to hip ratios, and lower LDLc and TC levels 
compared to CA females (p<0.05 for all).  
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Liver disease severity was associated with lipid profile measures. (Figures 5-1 and 5-2) 
Participants with severe fibrosis tended to have lower HDLc and TC levels compared to those 
with non-severe fibrosis (Figure 5-1: p=0.002 and 0.004, respectively), whereas participants with 
higher fat scores tended to have higher TG and lower HDLc levels (Figure 5-2: p<0.0001 and 
p=0.01 for trend, respectively). In regression models, serum ferritin and the percent iron/TIBC 
were associated with lipid profile measures in age and race-adjusted, and multivariable models 
(p<0.05). (Tables 5-3, 5-4, 5-6) The iron measures also differed significantly by steatosis, 
fibrosis, and hepatic iron score (p<0.05) (Table 5-7). Furthermore, in the multivariable model of 
LDLc (Table 5-6), a significant interaction (p<0.0001) was found between race and serum 
ferritin. Interpreted from the model as race-specific ferritin coefficients, the decline in LDLc per 
100 ng/mL increase in ferritin was significantly larger in CAs compared to AAs (CA: β=-3.4, 
p<0.0001; AA:  β=-1.7, p=0.0001).   
Significant direct relationships were found between the natural log of TG and log10 HCV 
RNA levels in unadjusted (β=0.11, p=0.003), age and race-adjusted (β=0.10, p=0.004), and 
multivariable regression models (β=0.09, p=0.01). (Figure 5-3, Table 5-3 and 5-6) Adjusting for 
age, LDLc concentrations were a mean 10.5 mg/dL lower among AAs than CAs. Adjusting for 
age and race, males had lower HDLc and TC levels, and higher TG levels, than females (on 
natural log scale β=-0.24, p<0.001, β=-0.07, p=0.002, β=0.14, p=0.14, respectively). (Tables 5-3 
and 5-4) Other factors associated with lipid profile measures in multivariable models (Table 5-6) 
were aspects of liver disease, including HAI inflammation which was inversely related to LDLc 
and the natural log of TC, severe Ishak fibrosis associated with lower natural log transformed 
HDLc levels (β=-0.10, p=0.006)), and fat score (directly related to the natural log of TG (β=0.17, 
p<0.001)). Among those using ACE inhibitors (n=31) to treat hypertension, levels were 
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significantly lower for LDLc (β=-21.2, p<0.001), and the natural logs of HDLc (β=-0.15, 
p=0.03) and TC (β=-0.09, p=0.02) compared to non-users in multivariable analyses.  
Using the NCEP ATP III definition, the prevalence of dyslipidemia was 70 percent in this 
cohort. (Table 5-4) Of those classified as dyslipidemic, low HDLc was the most common criteria 
of dyslipidemia (64%), followed by high TC (45%), high LDLc (43%), and high TG (32%). 
(Table 5-8)  Adjusting for age and race, the risk of dyslipidemia was significantly greater among 
males (30% higher risk compared to females, p=0.001), and was directly related to both BMI 
(10% increased risk per 5 unit increase in BMI, p=0.02) and waist to hip ratio. (Table 5-5) In 
multivariable regression models, a greater risk of dyslipidemia was associated with older age 
(10% excess risk per 10 year increase, p=0.03), male gender (30% higher risk compared to 
females, p=0.01), larger waist to hip ratio, and public health insurance (20% excess risk 
compared to private insurance, p=0.03), a possible surrogate of socioeconomic status. (Table 5-
6)  
5.5 DISCUSSION 
In this cohort of people with chronic HCV genotype 1 infection there was significant direct 
association between HCV and TG levels, the latter of which is related to VLDLc. This is relevant 
to proposed biological mechanisms of HCV replication and secretion from hepatocytes. 
Potentially important in the context of HCV-induced liver damage, steatosis was also associated 
with higher TG levels. In contrast to TG levels, other lipid profile measures were lower among 
those with advanced liver disease as measured by hepatic fibrosis, fat involvement, and 
inflammation.  
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The significant direct relationship between HCV and TG levels is consistent with 
findings from in vitro work suggesting that HCV is secreted from hepatocytes into the serum 
complexed with VLDL.29, 43-46 However, this observation is not compatible with findings of an 
inverse relationship between apolipoprotein B (the apolipoprotein corresponding to VLDL, TG, 
and LDL) and HCV levels in an epidemiologic study in a non-genotype 1 group.56 The 
inconsistency between in vitro and epidemiological studies may reflect unaccounted host factors 
in vitro experiments and genotype differences in in vivo experiments.  
In transgenic mouse models, inhibition of the microsomal triglyceride transfer protein by 
exposure to HCV core protein has been proposed as a mechanism of HCV-induced steatosis, a 
plausible basis for associations between hypobetalipoproteinemia and chronic HCV infection.46 
This mechanism is supported by two epidemiologic studies, which found inverse relationships 
between steatosis and TC, TG, and apolipoprotein B levels in a genotype 3 infected group, but 
not in genotype 1.56, 57 In contrast, there was a direct relationship between TG and liver fat score 
in the present study and in the larger Virahep-C cohort.58 The inconsistent relationships between 
steatosis and TG (or apolipoprotein B levels) may be attributed to the Virahep-C study being an 
exclusively genotype 1 infected group and that the etiology of steatosis may differ by HCV 
genotype.59, 60 Whereas steatosis is posited to occur due to metabolic changes that occur with 
genotype 1 infection, steatosis associated with genotype 3 infection may occur by a different 
direct viral-induced process.  
The current study found associations between steatosis and severe fibrosis with lower 
HDLc and severe fibrosis with lower TC levels. These findings are consistent with other findings 
from both non-HCV infected55 and chronically HCV infected groups56, 57 that have associated 
liver disease with lower levels of HDLc and TC. The inverse relationship between liver disease 
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and non-TG lipid profile measures may reflect the disruption of lipid and lipoprotein metabolism 
due to liver damage, albeit by host factors (e.g., poor nutrient intake, alcohol consumption, or 
excess body weight) or attributed to chronic HCV infection.6 
Despite lacking a defined biological role, serum iron measures (ferritin and the percent 
iron/TIBC) were related to the lipid profile (TG directly, other lipid profile measures indirectly). 
In addition, the iron measures were significantly higher for those with severe fibrosis, steatosis, 
or hepatic iron deposition. These findings are consistent with a report from a non-HCV exposed 
cohort, which found significantly lower HDLc and higher TG levels in a group with high ferritin 
levels of at least 100 ng/mL ferritin levels, compared to those below this cutpoint.66 Findings are 
also consistent with another study of exclusively HCV infected people, which found a direct 
relationship between ferritin and liver fat.14 Other work using National Health and Nutrition 
Examination Survey (NHANES) data has reported associations between elevated ferritin and 
iron saturation in HCV infected, compared to a non-exposed group of people.67-69 These studies 
suggest a relationship between serum iron measures, liver disease, and the lipid profile, which 
may be impacted by chronic HCV infection; however, biological mechanisms are unclear. 
Further investigation is warranted given the strong associations observed in this cohort.  
The current study estimated the prevalence of dyslipidemia, a risk factor for CVD,27 to be 
70 percent. Little is known about dyslipidemia or cardiovascular disease (CVD) risk in people 
with chronic HCV infection and the ability to compare findings across studies is limited due to 
different study population characteristics. In work based on a rural Egyptian study population, 
Marzouk et al. suggests that chronic HCV infection may correspond to a “favorable” CVD lipid 
profile based on observations of significantly lower TG and LDLc levels associated with chronic 
HCV infection (genotype not specified).48 In a Japanese cohort of chronically HCV infected 
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people (genotype not specified), CVD risk, as assessed by arteriosclerotic assessments with pulse 
wave velocity measures, did not differ significantly compared to a non-infected group, despite 
associations of infection with lower serum TG and TC levels.49 In contrast, chronic HCV 
infection has been associated with greater early atherosclerosis risk, as inferred through carotid 
intima-media thickness measurements in a cohort predominately infected with HCV genotype 1, 
compared to a non-infected group.51 Thus, despite the different lipid profile patterns associated 
with chronic HCV infection compared to non-infection, the relationship between chronic HCV 
infection and CVD risk is unclear.   
Given the cross-sectional nature of this analysis, this study is not without limitation, 
including the inability to infer causation or temporality of relationships between lipid profile and 
liver disease measures. In addition, the stepwise variable reduction approach used in 
multivariable modeling may also have influenced the results (refer to section 8.1 for details of 
stepwise modeling). It is possible that alternative modeling approaches, such as manually 
selecting variables and constructing multivariable models based on biological and clinical 
relevance, may have yielded different findings. For example, health insurance status was found 
to be a feature associated with dyslipidemia in multivariable analyses. However, this insurance 
status may serve as a proxy for other factors associated with socioeconomic status, such as race, 
educational attainment, and employment status, which may have entered the multivariable model 
if another modeling method was used.  
Despite these limitations, this study has a number of strengths in that it assessed factors 
associated with lipid profile measures, which may have implications to proposed mechanisms of 
HCV entry into hepatocytes, replication, and secretion from hepatocytes into the serum. In 
addition, the Virahep-C cohort, which by design enrolled and treated approximately equal 
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numbers of AAs and CAs, afforded a unique opportunity to assess if factors associated with the 
lipid profile differed by race. This study also characterized the prevalence and associated factors 
of dyslipidemia using a standard definition.  
In conclusion, the current study found associations between lipid profile measures and 
both HCV level and liver disease measures. In addition, this study found that dyslipidemia was a 
common occurrence, which may have implications for CVD risk. These findings may guide 
further investigations of the impact of antiviral therapy on the lipid profile, as well as the 
evaluation of lipid profile measures as predictors of treatment efficacy.  
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5.6 TABLES 
Table 5-1. Cohort characteristics (1 of 2) 
Feature* Overall (n=330) AA (n=160) CA (n=170) p 
Demographics     
Age (years) 48 (43,52) 48 (45,52) 47 (42,52) 0.07 
Male 216 (65.5) 106 (66.3) 110 (64.7) 0.77 
Health insurance (m=6)a    0.008 
     Uninsured 58 (17.9) 21 (13.4) 37 (22.2) 0.04 
     Public 79 (24.4) 49 (31.2) 30 (18.0) 0.006 
     Private 187 (57.7) 87 (55.4) 100 (59.9) 0.42 
Education (m=8)b    0.008 
      Less than high school  61 (18.9) 36 (23.1) 25 (15.1) 0.07 
      High school degree 78 (24.2) 41 (26.3) 37 (22.3) 0.16 
      Some college 105 (32.6) 50 (32.1) 55 (33.1) 0.16 
      College degree or more  78 (24.2) 29 (18.6) 49 (29.5) -- 
 Employed (m=4) 204 (62.6) 101 (63.9) 103 (61.3) 0.63 
Health risk behaviors     
 Current smoker (m=6) 128 (39.5) 65 (41.7) 63 (37.5) 0.44 
 Consumes > 2 alcoholic 
drinks/week (m=7) 
66 (20.4) 38 (24.2) 28 (16.9) 0.10 
General clinical features     
BMI (m=5) 28.4 (25.2,32.4) 29.3 (26.6,33.9) 27.4 (24.4,31.4) 0.0002 
    Male 28.5 (25.9,31.5) 28.5 (26.2,32.3) 28.4 (25.8,31.2) 0.35 
    Female 28.4 (24.0,34.1) 32.4 (27.2,36.0) 25.0 (22.3,31.7) <0.0001 
Waist to hip ratio (m=23) 0.9 (0.9,1.0) 0.9 (0.8,1.0) 0.9 (0.8,1.0) 0.44 
    Male 0.9 (0.9,1.0) 0.9 (0.9,1.0) 0.9 (0.9,1.0) 0.22 
    Female 0.8 (0.8,0.9) 0.9 (0.8,0.9) 0.8 (0.8,0.9) 0.008 
 Diabetic 31 (9.4) 24 (15.0) 7 (4.1) 0.0007 
 Hypertensive 97 (29.4) 64 (40.0) 33 (19.4) <0.0001 
Viral characteristics     
Log10 HCV level (m=1) 6.5 (5.6,6.7) 6.4 (5.6,6.7) 6.5 (5.6,6.8) 0.25 
HCV genotypec    0.002 
     1, NOS 25 (7.6) 10 (6.3) 15 (8.8) 0.38 
     1a 177 (53.6) 79 (49.4) 98 (57.7) 0.13 
     1a/b 11 (3.3) 1 (0.6) 10 (5.9) 0.01 
     1b 117 (35.5) 70 (43.8) 47 (27.7) 0.002 
m=number with missing data 
*Each categorical variable is summarized as n (%) with p-values corresponding to a Pearson’s chi-square test 
(nominal variables) or the Jonckheere-Terpstra test (ordinal variables) or exact equivalents, where appropriate; 
each continuous variable is summarized as a median (interquartile range) with a p-value corresponding to a 
Wilcoxon rank sum test.  
For features with two or more categories, the global p-value is listed in the first row of the feature.  
Where the global p-value is <0.05, p-values correspond to Pearson’s chi-square with comparisons as follows: 
aEach health insurance status category compared to other categories combined; bLess than high school vs. high 
school degree or more; high school degree vs. more than high school degree; some college vs. more than some 
college; cEach genotype compared to other categories combined  
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Table 5-2. Cohort characteristics (2 of 2) 
Feature* Overall (n=330) AA (n=160) CA (n=170) p 
Liver disease indicators     
ALT (IU/L) 69 (45,108) 60 (40,88) 74.5 (52,139) <0.0001 
AST (IU/L) 52 (37,79) 51.5 (35.5,71.5) 53 (38,87) 0.08 
Alk phosphatase (IU/L) 79 (62,103) 83 (62,108) 78 (63,96) 0.043 
Total bilirubin (mg/dL) 0.6 (0.5,0.8) 0.6 (0.4,0.8) 0.7 (0.5,0.9) 0.004 
INR (m=2) 1.0 (0.9,1.1) 1.0 (0.9,1.1) 1.0 (0.9,1.1) 0.95 
WBC count (103/mL) (m=3) 6.0 (4.7,7.3) 5.7 (4.6,7.3) 6.25 (4.9,7.4) 0.055 
Platelet count (103/mL) (m=4) 207.5 (161,257) 212 (159,268) 207 (161,242) 0.33 
Ferritin (ng/mL) (m=2) 204 (96.8,366) 246 (122,422) 149 (78,287) 0.0001 
Albumin (g/dL) (m=2) 4.2 (4.0,4.4) 4.2 (3.9,4.4) 4.2 (4.0,4.5) 0.004 
 Iron/TIBC (m=8) 34.1 (26.2,44.0) 33.9 (25.7,41.9) 34.3 (26.4,47.7) 0.18 
Ishak fibrosis score (m=1) 2 (1,3) 2 (1,3) 2 (1,3) 0.85 
 Ishak fibrosis score > 3 (m=1) 123 (37.4) 58 (36.5) 65 (38.2) 0.74 
Fat score (m=1) 0 (0,1) 0 (0,1) 0 (0,1) 0.19 
 Steatosis (>5  present) (m=1) 209 (63.5) 97 (61.0) 112 (65.9) 0.36 
Total HAI inflammation (m=1) 8 (6,10) 8 (7,10) 9 (6,11) 0.58 
Iron score (m=35)    0.09 
   0 157 (53.2) 66 (47.5) 91 (58.3)  
   1 115 (39.0) 62 (44.6) 53 (34.0)  
   2 23 (7.8) 11 (7.9) 12 (7.7)  
Serum lipid measures     
TG (mg/dL) 102.5 (75,146) 105.5 (74.5,151) 98.5 (76,137) 0.21 
     Male 106.5 (76,161) 112.5 (76,170) 105 (76,149) 0.23 
     Female 93.5 (74,134) 95.5 (72,139) 92.5 (76.5,122) 0.71 
LDLc (mg/dL) 115.1 (88.1,137.3) 106.4 (83.4,133.4) 118.7 (95.8,141.5) 0.009 
    Male 114.8 (87.2,134.2) 110.3 (86.4,131.3) 117.8 (89.8,137.6) 0.18 
    Female 116.6 (90.6,143.9) 104.9 (76.8,138.1) 122.5 (100.7,156.7) 0.009 
HDLc (mg/dL) 41.8 (33.7,53.8) 42.3 (32.9,54.6) 41.3 (33.8,52.0) 0.66 
     Male 38.3 (32.4,46.9) 39.3 (31.8,49.8) 37.2 (32.8,45.5) 0.38 
     Female 51.4 (39.4,61.4) 51.5 (38.0,51.5) 51.4 (41.2,59.5) 0.87 
TC (mg/dL) 185 (157,207) 179 (153.5,204.5) 187 (161,209) 0.10 
    Male 179 (155,204) 177.5 (152,204) 179.5 (155,205) 0.74 
    Female 189 (164,216) 184 (155,208) 192.5 (172.5,224.5) 0.02 
m=number with missing data 
*Each categorical variable is summarized as n (%) with p-values corresponding to a Pearson’s chi-
square test (nominal variables) or the Jonckheere-Terpstra test (ordinal variables) or exact 
equivalents, where appropriate; each continuous variable is summarized as a median (interquartile 
range) with a p-value corresponding to a Wilcoxon rank sum test.  
For features with two or more categories, the global p-value is listed in the first row of the feature.   
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   Table 5-3. Adjusted* regression models of lipid profile measures  
NOTE: Transformations as noted: ` =  natural log; ^ = 1 – reciprocal 
*Age and race adjusted unless otherwise specified as follows:  
       aAge-adjusted only; bRace-adjusted only 
**Per 10 unit increase;***Per 5 unit increase;****Per 100 unit increase
ln(TG) LDLc ln(HDLc) ln(TC) 
Feature β* (95%CI) p β* (95%CI) p β*  (95%CI) p β*  (95%CI) p 
Demographics         
AAa 0.1 (-0.04,0.2) 0.19 -10.5 (-18.3,-2.7) 0.008 0.02 (-0.05,0.09) 0.57 -0.04 (-0.08,0.01) 0.09 
Age (years)b** 0.03 (-0.04,0.1) 0.43 2.8 (-1.8,7.4) 0.23 -0.01 (-0.05,0.04) 0.74 0.02 (-0.02,0.04) 0.30 
Male 0.14 (0.03,0.25) 0.02 -6.6 (-15.0,1.9) 0.13 -0.24 (-0.31,-0.18) <0.001 -0.07 (-0.11,-0.03) 0.002 
Health risk behaviors         
Current smoker 0.13 (0.01,0.25) 0.03 5.2 (-3.2,13.5) 0.23 -0.05 (-0.13,0.02) 0.14 0.03 (-0.02,0.08) 0.21 
>2 Alcoholic drinks/week -0.03 (-0.15,0.10) 0.68 -4.9 (-14.4,4.6) 0.31 0.07 (-0.02,0.15) 0.13 -0.02 (-0.07,0.04) 0.53 
General clinical features         
BMI*** 0.07 (0.01,0.12) 0.01 1.6 (-1.7,4.8) 0.35 -0.05 (-0.08,-0.02) 0.002 0.004 (-0.01,0.02) 0.69 
Waist to hip ratio^ 0.45 (0.06,0.84) 0.03 2.1 (-29.5,33.7) 0.90 -0.74 (-1.04,-0.44) <0.001 -0.12 (-0.31,0.07) 0.21 
Diabetic 0.15 (-0.02,0.32) 0.08 -6.5 (-18.1,5.2) 0.28 -0.14 (-0.25,-0.02) 0.02 -0.05 (-0.12,0.02) 0.13 
Hypertensive 0.15 (0.02,0.29) 0.03 -11.7 (-20.4,-3.0) 0.008 -0.09 (-0.17,-0.01) 0.03 -0.06 (-0.11,-0.003) 0.04 
Viral characteristics         
Log10 HCV level  0.10 (0.03,0.18) 0.004 -0.2 (-5.1,4.7) 0.94 -0.03 (-0.08,0.01) 0.17 0.003 (-0.02,0.03) 0.83 
Liver disease indicators         
ALT (IU/L)` 0.02 (-0.06,0.11) 0.58 -4.4 (-10.2,1.4) 0.14 -0.07 (-0.12,-0.02) 0.01 -0.04 (-0.08,-0.003) 0.03 
AST (IU/L)` 0.08 (-0.01,0.18) 0.09 -7.2 (-13.9,-0.6) 0.03 -0.06 (-0.12,0.0004) 0.052 -0.04 (-0.08,-0.004) 0.03 
Alk phosphatase (IU/L)` 0.40 (0.26,0.55) <0.001 -9.2 (-19.9,1.5) 0.09 -0.10 (-0.20,0.01) 0.07 -0.02 (-0.09,0.04) 0.51 
Total bilirubin (mg/dL)^ -0.03 (0.23,0.02) 0.23 0.04 (-3.7,3.8) 0.98 -0.01 (-0.03,0.02) 0.72 -0.01 (-0.03,0.02) 0.63 
INR -0.31 (-0.78,0.15) 0.19 -8.2 (-43.6,27.3) 0.65 -0.26 (-0.53,0.001) 0.051 -0.18 (-0.39,0.04) 0.10 
WBC count (103/mL) 0.03 (0.01,0.06) 0.02 0.9 (-1.0,2.8) 0.36 -0.03 (-0.05,-0.02) <0.001 0.002 (-0.01,0.01) 0.73 
Platelet count (103/mL)**** -0.03 (-0.11,0.05) 0.43 9.2 (3.8,14.6) 0.001 0.05 (-0.002,0.1) 0.06 0.06 (0.03-0.09) <0.001 
Ferritin (ng/mL)**** 0.03 (0.02,0.05) <0.001 -1.9 (-3.1,-0.8) 0.001 -0.02 (-0.03,-0.005) 0.005 -0.01 (-0.02,-0.003) 0.004 
%Iron/TIBC** -0.0001 (-0.02,0.01) 0.91 -0.9 (-2.5,0.6) 0.24 -0.01 (-0.02,-0.002) 0.02 -0.01 (-0.02,0.002) 0.12 
Total HAI inflammation^ 0.39 (-0.71,1.48) 0.49 -106.8 (-175.1,-38.5) 0.002 -0.36 (-0.94,0.21) 0.22 -0.62 (-0.98,-0.26) 0.001 
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Table 5-4. Cohort characteristics by dyslipidemic status 
Dyslipidemia 
Feature Yes (n=232) No (n=98) 
Demographics   
AA 110 (68.8)  
CA 122 (71.8)  
Age (years) 48 (44,52.5) 46.5 (42,51) 
Male 166 (76.9)  
   Female 66 (57.9)  
Health insurance   
   Uninsured 44 (75.9)  
   Public 58 (73.4)  
   Private 124 (66.3)  
Educational attainment    
    <High school 47 (77.1)  
    High school degree 57 (73.1)  
    Some college 65 (61.9)  
    >College degree 56 (71.8)  
Employed  142 (69.6)  
    Unemployed 86 (70.5)  
Health risk behaviors   
Current smoker 95 (74.2)  
    Non-smoker 131 (66.8)  
Alcohol consumption   
   >2 drinks/week 42 (63.6)  
   <2 drinks/week 185 (72.0)  
General clinical features   
BMI 29.0 (26.0,32.6) 27.3 (24.0,31.0) 
  Male 28.8 (26.2,32.0) 27.7 (24.7,30.0) 
  Female 30.3 (25.0,34.9) 26.9 (23.3,33.8) 
Waist to hip ratio 0.9 (0.9,1.0) 0.9 (0.8,0.9) 
  Male 0.9 (0.9,1.0) 0.9 (0.9,1.0) 
  Female 0.9 (0.8,0.9) 0.8 (0.8,0.9) 
Diabetic 24 (77.4)  
   Non-diabetic 208 (69.6)  
Hypertensive 68 (70.1)  
   Non-hypertensive 164 (70.4)  
Viral characteristics   
Log10 HCV level  6.5 (5.7,6.8) 6.3 (5.6,6.7) 
*Each categorical variable is summarized as n (%) and each continuous variable is summarized as a median 
(interquartile range).  
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Table 5-5. Relative risk of dyslipidemia  
Dyslipidemia 
Feature RR* (95%CI) p 
Demographics   
AAa 0.9 (0.8,1.1) 0.44 
Age (years)b** 1.1 (0.98,1.2) 0.14 
Male 1.3 (1.1,1.6) 0.001 
Health insurancec  0.16 
   Public 0.9 (0.8,1.2) 0.56 
   Private 0.8 (0.7,1.02) 0.08 
Educational attainmentd   0.12 
   High school degree 0.9 (0.8,1.1) 0.55 
   Some college 0.8 (0.7,0.96) 0.02 
   >College degree 0.9 (0.7,1.1) 0.26 
Employed  1.003 (0.9,1.2) 0.97 
Health risk behaviors   
Current smoker 1.1 (0.98,1.3) 0.09 
>2 Alcoholic drinks/week 0.9 (0.7,1.1) 0.30 
General clinical features   
BMI*** 1.1 (1.01,1.2) 0.02 
Waist to hip ratio^ 2.8 (1.5,5.1) 0.001 
Diabetic 1.1 (0.9,1.4) 0.29 
Hypertensive 0.97 (0.8,1.1) 0.70 
Viral characteristics   
Log10 HCV level  1.1 (0.97,1.2) 0.16 
Transformations as follows:` = natural log; ^ = 1  – reciprocal 
*Age and race adjusted unless otherwise specified as follows: aAge-adjusted only; bRace-adjusted only 
Reference group for regression models as follows: cUninsured; dLess than high school degree; 
**Per 10 unit increase 
***Per 5 unit increase 
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Table 5-6. Multivariable regression models of dyslipidemia and lipid profile measures 
Dyslipidemia ln(TG) LDLc ln(HDLc) ln(TC) 
Feature 
RR 
(95%CI) 
p β (95%CI) p β (95%CI) p β (95%CI) p β (95%CI) p 
AA Race~ 0.9 (0.8,1.1) 0.21 0.05 (-0.06,0.15) 0.37 -8.0 (-15.6,-0.3) 0.04 0.01 (-0.05,0.08) 0.68 -0.04 (-0.08,0.004) 0.08 
Age (years)~* 1.1 (1.01,1.2)  0.03 -0.001 (-0.06,0.06) 0.96 5.1 (0.4,9.7) 0.03 -0.002 (-0.05,0.04) 0.93 0.04 (0.01,0.06) 0.02 
Male 1.3 (1.1,1.5) 0.01       -0.06 (-0.10,-0.01) 0.01 
Health insurancea   0.04         
  Public 0.99 (0.8,1.2) 0.93         
  Private 0.8 (0.7,1.01) 0.06         
Waist to hip ratio^ 2.1 (1.1,4.1) 0.02     -0.61 (-0.91,-0.31) <0.001   
Hypertensive treatment           
  ACE inhibitors     -21.2 (-32.3,-10.0) <0.001 -0.15 (-0.28,-0.01) 0.03 -0.09 (-0.17,-0.01) 0.02 
  Diet         -0.15 (-0.28,-0.03) 0.02 
Log10 HCV level   0.09 (0.02,0.16) 0.01       
Alk phosphatase (IU/L)`   0.34 (0.20,0.48) <0.001       
WBC count (103/mL)       -0.03 (-0.04,-0.01) 0.001   
Platelet count (103/mL)$         0.04 (0.01,0.07) 0.01 
Ferritin (ng/mL)$   0.02 (0.01,0.03) 0.003 -3.4 (-4.8,-1.9) <0.001     
Ferritin$ X Race      0.001     
    AA     -1.7 (-2.8,-0.7) 0.001     
    CA     -3.4 (-4.8,-1.9) <0.001     
%Iron/TIBC*       -0.01 (-0.02,-0.005) 0.001   
Total HAI inflammation^     -86.3 (-154.2,-18.4) 0.01   -0.43 (-0.80,-0.06) 0.02 
Ishak fibrosis score > 3       -0.10 (-0.17,-0.03) 0.006   
Fat score   0.17 (0.09,0.25) <0.001       
Transformed scale as noted: ` = natural log; ^ = 1 – reciprocal 
~Forced into the multivariable model 
aUninsured reference group; *Per 10 unit increase; $Per 100 unit increase 
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 Table 5-7. Iron status and liver biopsy measures by race 
AA CA Overall Iron saturation and 
liver biopsy measure Median (IQR) p* Median (IQR) p* Median (IQR) p* 
Ferritin (ng/mL)       
Ishak fibrosis score > 3 295 (176,545) 0.06 245 (127,411) <0.0001 263 (139,472) <0.0001 
   <3 223.5 (105,404.5)  125.5 (53.5,245)  167.5 (77.5,302.5)  
Steatosis (>5% present) 264 (128,516) 0.06 203 (114,337) 0.004 239 (120,414) 0.0005 
  No steatosis 214 (94,357)  109.5 (44,196)  160 (75,291)  
HAI scores  0.95  0.01  0.07 
   0–6 (mild) 266 (82.7,422)  97.5 (33.9,265.5)  132 (60,339)  
   7–11 (moderate) 241 (125,478)  191 (113,300)  218 (116,374)  
   >12 (severe) 264 (143,388)  168 (77,379)  192 (91.8,379)  
Iron score  <0.0001  <0.0001  <0.0001 
   0 127 (76,233)  107 (38,187)  115 (53.5,198.5)  
   1 373 (242,545)  268 (173,470)  331.5 (218,514)  
   2 613 (474, 955)  359 (216,558.5)  527 (285,663)  
%Iron/TIBC        
Ishak fibrosis score > 3 36.9 (27.7,44.1) 0.02 36.2 (27.7,51.8) 0.17 36.5 (27.7,46.6) 0.01 
   <3 31.2 (23.8,40.2)  33.3 (26.2,45.8)  32.4 (25.4,41.9)  
Steatosis (>5% present) 34.1 (26.9,41.9) 0.41 35.6 (27.6,49.3) 0.27 34.8 (27.3,45.1) 0.17 
  No steatosis 33.5 (22.6,40.8)  33.8 (25.9,41.9)  33.7 (24.4,41.9)  
HAI scores  0.63  0.35  0.34 
   0–6 (mild) 29.3 (23.8,41.3)  31.2 (25.7,45.7)  32.2 (24.6,42.1)  
   7–11 (moderate) 34.5 (26.3,42.5)  37.1 (28.4,49.3)  35.7 (27.1,44.6)  
   >12 (severe) 34.6 (28.0,39.8)  31.9 (26.7,44.4)  33.5 (26.9,39.8)  
Iron score  <0.0001  <0.0001  <0.0001 
   0 27.4 (22.1,37.3)  33.2 (24.4,42.1)  31.2 (23.5,39.3)  
   1 37.4 (30.4,43.3)  36.5 (27.7,46.6)  37.3 (29.0,44.8)  
   2 51.4 (28.5,67.0)  53.4 (36.2,58.6)  51.9 (32.2,61.2)  
*p-values correspond to Wilcoxon rank sum or Kruskal-Wallis tests for differences in iron saturation across liver biopsy measures  
Table 5-8. Criteria for dyslipidemia 
High 
TC 
High 
LDLc 
High 
TG 
Low 
HDLc n (%) 
      X 69 (29.7) 
X X     48 (20.7) 
    X X 33 (14.2) 
X X X X 18 (7.8) 
X X   X 14 (6.0) 
X       12 (5.1) 
    X   11 (4.7) 
  X   X 9 (3.9) 
  X     6 (2.6) 
X   X X 5 (2.2) 
X X X   4 (1.7) 
X   X   3 (1.3) 
104 99 74 148 232 
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Table 5-9. Supplement 1: Dyslipidemia by additional features 
Dyslipidemia 
Feature Yes (n=232) No (n=98) 
Viral characteristics   
HCV genotype   
     1, NOS 18 (72.0)  
     1a 126 (71.2)  
     1b 9 (81.8)  
     1a/1b 79 (67.5)  
Liver disease indicators   
ALT (IU/L) 71 (47,110) 63.5 (42,104) 
AST (IU/L) 54 (38,79) 49 (33,76) 
Alk phosphatase (IU/L 79 (63.5,103) 79.5 (61,102) 
Total bilirubin (mg/dL) 0.6 (0.5,0.8) 0.6 (0.4,0.8) 
INR 1.0 (0.9,1.1) 1.0 (0.9,1.1) 
WBC count (103/mL) 6.1 (4.8,7.5) 5.5 (4.5,7.0) 
Platelet count (103/mL) 210 (161,257) 206 (163,257) 
Ferritin (ng/mL)  204 (94,365) 203 (102,367) 
Albumin (mg/dL) 4.2 (4.0,4.4) 4.2 (4.0,4.4) 
 Iron/TIBC 33.2 (25.9,42.9) 35.9 (27.4,44.2) 
Ishak score 2 (1,3) 2 (1,3) 
 Ishak fibrosis score > 3 88 (71.5)  
    <3 143 (69.4)  
Fat score 0 (0,1) 0 (0,1) 
 Steatosis (>5  present) 153 (73.2)  
   No steatosis 78 (65.0)  
Total HAI inflammation 9 (6, 11) 8 (6, 10) 
Iron score   
   0 105(66.9)  
   1 88 (76.5)  
   2 15 (65.2)  
*Each categorical variable is summarized as n (%) and each continuous variable is summarized as a median 
(interquartile range). 
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Table 5-10. Supplement 2: Relative risk of dyslipidemia (additional features) 
Dyslipidemia 
Feature RR* (95%CI) p 
Viral characteristics   
HCV genotypea   
    1, NOS 0.997 (0.8,1.3) 0.98 
    1b 1.1 (0.8,1.6) 0.39 
    1a/1b 0.9 (0.8,1.1) 0.38 
Liver disease indicators   
ALT (IU/L)` 1.1 (0.96,1.2) 0.24 
AST (IU/L)` 1.1 (0.9,1.2) 0.37 
Alk phosphatase (IU/L)` 1.1 (0.9,1.3) 0.36 
Total bilirubin (mg/dL)^ 1.02 (0.9,1.1) 0.63 
INR 1.4 (0.8,2.5) 0.21 
WBC count (103/mL) 1.04 (1.003,1.1) 0.03 
Platelet count (103/mL)**** 0.997 (0.9,1.1) 0.96 
Ferritin (ng/mL)**** 1.002 (0.97,1.02) 0.86 
Albumin (g/dL) 1.1 (0.9,1.3) 0.41 
%Iron/TIBC** 1.003 (0.99,1.01) 0.67 
Ishak score 1.02 (0.97,1.1) 0.45 
   Ishak score > 3 1.003 (0.9,1.2) 0.97 
Fat score 1.1 (0.997,1.2) 0.06 
   Steatosis (>5% present) 1.1 (0.95,1.3) 0.17 
Total HAI inflammation^ 1.2 (0.4,4.0) 0.75 
Iron scoreb  0.18 
   1 1.1 (0.98,1.3) 0.08 
   2 0.97 (0.7,1.3) 0.87 
NOTE: Transformations as noted: ` = natural log; ^ = 1 – reciprocal 
aHCV genotype 1a reference; b0 Iron score reference 
**Per 10 unit increase; ****Per 100 unit increase 
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 Table 5-11. Supplement 3. Lipid profile measures in subgroups 
*p-value corresponds to the Wilcoxon rank sum or Kruskal-Wallis test 
 
LDLc  HDLc  TC TG 
Feature Median (IQR) p* Median (IQR) p* Median (IQR) p* Median (IQR) p* 
Gender  0.33  <0.001  0.008  0.02 
   Male 114.8 (87.2,134.2)  38.3 (32.4,46.9)  179 (155,204)  106.5 (76,161)  
   Female 116.6 (90.6,143.9)  51.4 (39.4,61.4)  189 (164,216)  93.5 (74,134)  
Health insurance  0.46  0.96  0.83  0.07 
   Uninsured 116.7 (87.0,134.6)  41.1 (33.5,57.6)  185.5 (151,208)  89 (69,126)  
   Public 104.5 (83.5,138.1)  40.0 (34.4,56.5)  185 (154,205)  110 (86,149)  
   Private 116.5 (91.0,137.2)  42.5 (33.4,52.0)  183 (160,206)  100 (74,147)  
Educational attainment   0.41  0.20  0.33  0.81 
     <High school 121.8 (86.9,140.4)  40.9 (32.6,54.7)  188 (159,207)  114 (76,149)  
     High school degree 115.6 (83.5,137.3)  38.7 (32.7,49.9)  179 (152,205)  97 (73,129)  
     Some college 111.5 (85.0,132.4)  45.4 (34.7,56.0)  183 (150,206)  100 (77,141)  
     >College degree 115.2 (94.5,143.4)  44.3 (34.7,54.1)  185 (165,209)  99 (76,144)  
Employed 114.8 (89.6,137.1) 0.68 42.2 (33.4,51.9) 0.32 181 (158.5,206.5) 0.9995 100 (74,146) 0.94 
   Unemployed 115.2 (85.0,137.6)  41.8 (34.7,57.7)  186 (154,206)  101 (75,146)  
Current smoker 113.1 (85.8,142.4) 0.66 40.6 (33.3,52.6) 0.17 185.5 (157,210) 0.52 108 (80,156.5) 0.07 
   Non-smoker 115.1 (88.7,132.8)  43.6 (33.8,54.3)  182.5 (157,205)  98 (73.5,138)  
Alcohol consumption  0.40  0.12  0.70  0.68 
  >2 drinks/week 112.0 (81.7,136.7)  45.9 (35.7,53.8)  187 (150,205)  99 (74,144)  
  <2 drinks/week 115.5 (89.8,137.6)  40.8 (33.4,54.1)  183 (159,207)  105 (76,146)  
Diabetic 104.5 (86.4,126.8) 0.17 37.9 (30.6,50.7) 0.045 162 (150,196) 0.14 123 (96,165) 0.02 
   Non-diabetic 116.2 (89.2,139.9)  42.3 (33.8,54.4)  158 (139,185)  99 (74,143)  
Hypertensive 105.6 (80.8,129.9) 0.02 39.4 (31.5,52.0) 0.07 180 (149,201) 0.06 108 (79,171) 0.04 
   Non-hypertensive 117.8 (91.6,141.3)  42.3 (34.4,55.2)  185 (160,209)  99 (74,138)  
HCV genotype  0.77  0.68  0.57  0.26 
    1, NOS 114.0 (90.6,155.8)  46.1 (34.8,53.2)  195 (150,219)  115 (80,164)  
    1a 115.4 (88.1,137.3)  41.1 (33.7,52.1)  180 (160,205)  96 (73,138)  
    1b 114.6 (87.6,134.2)  42.1 (33.5,54.2)  188 (154,206)  104 (78,146)  
    1a/1b 118.7 (94.5,135.2)  37.1 (28.9,45.0)  176 (163,195)  108 (83,183)  
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Table 5-12. Supplement 4: Adjusted regression models of lipid fraction (additional features) 
ln(TG) LDLc ln(HDLc) ln(TC) 
Feature β* (95%CI) p β* (95%CI) p β*  (95%CI) p β*  (95%CI) p 
Demographics         
Health insurancea  0.27  0.87  0.91  0.97 
   Public 0.11 (-0.06,0.28) 0.21 -0.2 (-13.3,12.9) 0.98 -0.0009 (-0.11,0.11) 0.99 0.01 (-0.07,0.08) 0.83 
   Private 0.01 (-0.14,0.17) 0.88 2.1 (-9.0,13.3) 0.71 -0.02 (-0.11,0.08) 0.73 0.01 (-0.06,0.07) 0.80 
Educational attainmentb   0.92  0.48  0.16  0.28 
   High school degree -0.06 (-0.24,0.13) 0.54 -5.4 (-16.4,5.7) 0.25 -0.04 (-0.14,0.06) 0.44 -0.05 (-0.12,0.01) 0.13 
   Some college -0.06 (-0.22,0.11) 0.51 -6.5 (-17.6,4.6) 0.25 0.06 (-0.05,0.16) 0.30 -0.04 (-0.10,0.03) 0.24 
   >College degree -0.04 (-0.21,0.13) 0.65 0.4 (-11.1,11.9) 0.95 0.05 (-0.07,0.16) 0.43 -0.001 (-0.07,0.06) 0.97 
Employed  -0.02 (-0.13,0.10) 0.79 0.8 (-7.5,9.0) 0.85 -0.04 (-0.11,0.03) 0.28 -0.01 (-0.05,0.04) 0.82 
Health risk behaviors         
Current smoker 0.13 (0.01,0.25) 0.03 5.2 (-3.2,13.5) 0.23 -0.05 (-0.13,0.02) 0.14 0.03 (-0.02,0.08) 0.21 
>2 Alcoholic drinks/week -0.03 (-0.15,0.10) 0.68 -4.9 (-14.4,4.6) 0.31 0.07 (-0.02,0.15) 0.13 -0.02 (-0.07,0.04) 0.53 
General clinical features         
BMI: Males*** 0.09 (0.01,0.18) 0.03 2.1 (-1.9,6.2) 0.30 -0.07 (-0.10,-0.03) 0.001 0.01 (-0.02,0.04) 0.42 
BMI: Female*** 0.05 (-0.01,0.10) 0.10 1.8 (-3.4,7.1) 0.49 -0.04 (-0.08,-0.004) 0.03 -0.001 (0.03,0.02) 0.95 
Waist to hip ratio: Male^ 0.10 (-0.54,0.75) 0.75 22.6 (-21.7,67.0) 0.32 -0.27 (-0.68,0.14) 0.19 0.09 (-0.18,0.36) 0.52 
Waist to hip ratio: Female^ 0.53 (0.02,1.05) 0.04 9.3 (-43.2,61.9) 0.73 -0.68 (-1.07,-0.30) 0.001 -0.12 (-0.40,0.16) 0.40 
Viral characteristics         
HCV genotypec  0.14  0.68  0.75  0.48 
    1, NOS 0.15 (-0.06,0.37) 0.16 9.6 (-9.1,28.2) 0.32 0.03 (-0.10,0.16) 0.63 0.07 (-0.02,0.17) 0.14 
    1b 0.17 (-0.06,0.40) 0.15 3.0 (-23.1,17.1) 0.77 -0.11 (-0.34,0.13) 0.38 -0.01 (-0.12,0.10) 0.80 
    1a/1b 0.11 (-0.02,0.23) 0.09 -2.1 (-10.3,6.1) 0.61 0.01 (0.06,0.09) 0.70 0.01 (-0.03,0.06) 0.56 
Liver disease indicators         
Ishak fibrosis score 0.02 (-0.02,0.06) 0.28 -3.3 (-6.0,-0.5) 0.02 -0.04 (-0.06,-0.01) 0.003 -0.03 (-0.04,-0.01) 0.001 
Ishak fibrosis score > 3 0.05 (-0.07,0.16) 0.43 -9.1 (-17.2,-1.01) 0.03 -0.11 (-0.18,-0.04) 0.001 -0.08 (-0.12,-0.03) 0.001 
Fat score 0.22 (0.14,0.30) <0.001 -4.4 (-10.5,1.7) 0.15 -0.07 (-0.13,-0.01) 0.02 -0.01 (-0.04,0.03) 0.61 
   Steatosis (>5% present) 0.21 (0.11,0.32) <0.001 -7.3 (-15.5,1.0) 0.08 -0.09 (-0.16,-0.02) 0.01 -0.03 (-0.07,0.02) 0.27 
Iron scored  0.21  0.64  0.01  0.43 
   1 0.11 (-0.01,0.23) 0.08 -4.0 (-12.6,4.5) 0.36 -0.11 (-0.19,-0.04) 0.004 -0.03 (-0.08,0.02) 0.19 
   2 0.02 (-0.23,0.27) 0.86 -0.5 (-16.5,15.6) 0.96 -0.08 (-0.22,0.05) 0.24 -0.01 (-0.10,0.07) 0.78 
Transformation as noted: ` = natural log; ^ = 1 – reciprocal 
*Age and race adjusted 
Reference group for regression models as follows: aUninsured; bLess than high school degree; c1a genotype; d0 Iron score 
**Per 10 unit increase; ***Per 5 unit increase; ****Per 100 unit increase 
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Table 5-13. Supplement 5: Adjusted* regression models of dyslipidemia and lipid profile measures (hypertension treatments) 
Dyslipidemia ln(TG) LDLc ln(HDLc) ln(TC) 
Treatment RR (95%CI) p β (95%CI) p β (95%CI) p β (95%CI) p β (95%CI) p 
Hypertension Txa           
  Calcium channel  
  blockers  (n=24) 
0.9 (0.7,1.3) 0.58 0.12 (-0.13 – 0.37) 0.36 -1.0 (-16.3,14.3) 0.90 0.07 (-0.05,0.20) 0.23 0.04 (-0.04,0.12) 0.36 
  Diet (n=8) 1.02 (0.7,1.5) 0.91 -0.13 (-0.47 – 0.22) 0.48 -17.9 (-41.9,6.0) 0.14 -0.17 (-0.36,0.02) 0.08 -0.16 (-0.29,-0.03) 0.02 
  Diuretic (n=27) 1.2 (0.9,1.1) 0.15 0.31 (0.05 –0.57) 0.02 -5.4 (-19.0,8.2) 0.43 -0.13 (-0.26,-0.01) 0.04 0.001 (-0.08,0.08) 0.97 
  ACE inhibitors  
  (n=25) 
1.1 (0.9,1.4) 0.28 0.24 (-0.04 – 0.52) 0.09 -21.9 (-33.6,-10.2) <0.001 -0.16 (-0.30,-0.02) 0.02 -0.11 (-0.19,-0.03) 0.007 
  Beta blockers    
  (n=21) 
0.9 (0.7,1.3) 0.71 0.28 (0.07 – 0.49) 0.009 -10.7 (-23.7,2.4) 0.11 -0.10 (-0.26,0.06) 0.24 -0.03 (-0.11,0.04) 0.39 
*Race and age adjusted models 
Reference group for regression models as follows: aNo treatment for hypertension
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5.7 FIGURES 
 
Figure 5-1. Lipid profile measures by Ishak fibrosis score 
p-values correspond to Wilcoxon rank sum tests of differences by fibrosis score (Ishak fibrosis score > 3 vs Ishak 
fibrosis score <3) 
NOTE: Boxplots exclude three extreme TG level outliers: 600 and 980 mg/dL (non-severe fibrosis); 481 mg/dL 
(severe fibrosis).  
 
 
  44
 
Figure 5-2. Lipid measures by liver fat score 
p-values correspond to a test of trend with fat score. (Trend test for TG, HDLc, and TC on the natural log scale) 
NOTE: Boxplots exclude three extreme TG level outliers: 980 mg/dL (fat score=0.5); 481 and 600 mg/dL 
(fatscore=1).  
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Figure 5-3. Relationship between TG and HCV RNA level 
ln=natural log transformation 
Back-transformed, one log10 increase in HCV level corresponds to an 11.4 mg/dL TG increase on the raw scale. 
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6.0  PROJECT 2: RACE AND CHANGES IN THE SERUM LIPID PROFILE 
DURING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C INFECTION 
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6.1 ABSTRACT 
BACKGROUND: Few studies have assessed the impact of antiviral therapy on the lipid profile 
in HCV infection and findings are inconsistent. AIM: To characterize changes in the lipid profile 
in a chronic HCV genotype 1 infected cohort undergoing combination PEG-IFN alfa-2a + 
ribavirin therapy. METHODS: Data were drawn from the Virahep-C study, an investigation of 
resistance to therapy among 401 participants who underwent up to 48 weeks of therapy. This 
analysis is based on 288 participants (135 African American (AA) and 153 Caucasian American 
(CA)) who had at least 1 post-baseline fasting serum sample. The on-treatment lipid profile 
assessment was conducted using stored serum collected after 24 weeks of therapy and the post-
therapy assessment 24 weeks after the cessation of therapy. Generalized estimating equation 
(GEE) models were used to assess changes in the lipid profile during therapy and to evaluate 
racial differences. RESULTS: After 24 weeks of therapy triglyceride (TG) levels were 
significantly greater than pretreatment and low density lipoprotein cholesterol (LDLc), high 
density lipoprotein cholesterol (HDLc), and total cholesterol (TC) levels were significantly 
lower. Declines during the first 24 weeks of therapy in LDLc and TC were significantly 
associated with the amount of PEG-IFN taken. Post-therapy, significant changes in the lipid 
profile from baseline were found only among participants who underwent a 48-week course of 
therapy. In this group, TG, LDLc, and TC levels were significantly higher than pretreatment 
levels. The relationship between race and changes from pretreatment to 24 weeks of treatment in 
TG, LDLc, and TC differed with CAs having larger increases in TG and larger declines in LDLc 
and TC than AAs. CONCLUSIONS: Antiviral therapy is associated with changes in the lipid 
profile during and after antiviral therapy, with the changes differing by race and the amount of 
PEG-IFN taken. This suggests that the lipid profile may be involved in mechanisms of antiviral 
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therapy and HCV eradication. Further investigations are warranted to determine if lipid profile 
measures predict treatment efficacy and if the difference in lipid profile between AAs and CAs 
explain the racial disparity response to treatment.  
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6.2 INTRODUCTION 
Chronic HCV infection is a major public health problem in the United States (US) afflicting at 
least 3.2 million persons (1.3%) with an estimated direct health care cost of $1.8 billion 
annually.3, 25 The current standard treatment, combination PEG-IFN and ribavirin, is not 
completely effective and virological response for genotype 1, the predominant form of HCV in 
the US, differs by race with African Americans (AAs) having lower rates sustained virological 
response (SVR) (19–28%) than Caucasian Americans (CAs) (39–52%).10-12 Reasons for the 
racial disparity in efficacy are unknown.10 
Recent in vitro work suggests that serum lipoproteins, lipoprotein receptors, and 
cholesterol metabolism may mask HCV from the host immune response, provide a means of 
HCV entry into hepatocytes, and play a central role in HCV replication and secretion from 
hepatocytes into the serum.29-37, 40-46 Furthermore, interferon exposure has been shown to down-
regulate scavenger receptor B-1 expression, potentially relevant to mechanisms of interferon-
induced HCV eradication.72 The down-regulation of scavenger receptor B-1, a receptor involved 
in the uptake of high density lipoprotein into hepatocytes from the serum,27 suggests that 
interferon therapy may also influence lipoprotein levels.  
In trials evaluating factors associated with virological response to treatment, low density 
lipoprotein cholesterol (LDLc) and total cholesterol (TC) levels have been directly related to 
virological response.61-65 In addition, comparing sustained virological responders to non-
responders, another study found that responders tended to have significantly higher pretreatment 
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triglyceride (TG) levels, whereas TC levels did not significantly differ.52 These findings suggest 
that lipid profile measures may be important predictors of virological response. 
The lipid profile has also been reported to change over the course of interferon therapy, 
although the results are inconsistent and differ by HCV genotype. Compared to pretreatment, 
interferon mono-therapy has been associated with increases in TC and TG levels, with TC levels 
remaining significantly higher and TG levels returning to pretreatment levels after stopping 
therapy.52 Other work found significant increases in TG levels, and no significant change in TC 
levels.53 Compared to pretreatment, significant increases in TC have been reported in a subgroup 
with HCV genotype 3, but not genotype 1 during therapy54, whereas another study reported 
higher TG levels during therapy in a group with genotype 1, but not in non-genotype 1.53  
Findings from in vitro and epidemiological studies suggest the involvement of the serum 
lipid profile in mechanisms of antiviral therapy and treatment response. This study characterizes 
changes in the serum lipid profile over the course of combination antiviral therapy in an HCV 
genotype 1 infected cohort. In addition, this study assesses pretreatment patient and disease 
characteristics that predict changes in the lipid profile during and after therapy.  
6.3 METHODS 
6.3.1 Study population 
Participants were drawn from the Virahep-C study, an investigation of resistance to antiviral 
therapy that has been described elsewhere.10 In brief, Virahep-C enrolled and treated 
approximately equal numbers of CA (n=205) and AA (n=196) participants who underwent a 
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combination antiviral regimen of PEG-IFN alfa-2a and ribavirin for up to 48 weeks for chronic 
HCV infection, genotype 1. The primary aim of the Virahep-C study was to investigate clinical, 
immunological, virological, and host genetic factors involved in the resistance to antiviral 
treatment, and in particular, racial differences in virological response.  Funding for lipid profile 
analyses was obtained for participants in an ancillary study to Virahep-C examining the 
relationship between host genetic polymorphisms, the lipid profile, and steatosis (KL2 
RR024154-02 to LJY). Therefore, only those who granted genetic consent (n=374) were eligible 
for this investigation. Stored fasting serum samples were available for 330 of the participants 
before treatment, for 253 of these 24 weeks after beginning therapy, and for 239 participants 24 
weeks after stopping therapy. Among the 239 post-treatment samples, 177 were from 
participants who were 6 month virological responders who had undergone a 48 week course of 
therapy, and 62 were from 6 month virological non-responders who had only a 24 week course 
of therapy. The final sample for this analysis consisted of 288 participants (135 AA and 153 CA) 
who had a pretreatment and at least 1 available post-baseline stored fasting serum sample.   
6.3.2 Study measures 
Estimates of the lipid profile fractions, TG, LDLc, HDLc, and TC, were obtained through 
analyzing stored fasting serum samples at the Heinz Nutrition Laboratory in the Department of 
Epidemiology, University of Pittsburgh. If TG levels were less than 400 mg/dL, the Friedewald 
formula was used to calculate LDLc indirectly (LDLc = TC − HDLc − 0.20 X TG).28 For 
samples with TG levels of 400 mg/dL or greater, LDLc was assessed directly. Dyslipidemia was 
defined using the cutoffs from the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP) III recommendations as any of the following: LDLc greater than or equal 
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to 130 mg/dL, HDLc less than 40 mg/dL, TC greater than or equal to 200 mg/dL, or TG greater 
than or equal to 150 mg/dL.70  An Ishak fibrosis score of at least 3 was classified as severe 
fibrosis and steatosis was defined as a fat score of greater than zero representing at least 5% fat 
involvement of hepatic tissue. Total HAI inflammation, Ishak fibrosis, and fat scores were also 
analyzed as continuous parameters. Inflammation and fibrosis were assessed using the criteria of 
the Histological Activity Index (HAI) by a single hepatopathologist.19, 20 The amount of PEG-
IFN and ribavirin taken by participants was estimated using data from the Medication Event 
Management System (MEMS) (Aardex, Zug, Switzerland).73  
 
6.3.3 Statistical analysis 
Categorical measures were summarized as frequency and percent with differences across 
nominally classified groups (i.e., race, gender, health insurance status, employment status, 
smoking status, alcohol consumption of at least 2 drinks per week, history of diabetes and 
hypertension, HCV genotype, and severe fibrosis) assessed using a Pearson’s chi-square test or 
the exact equivalent. Differences in categorical measures across ordinal groups (i.e., educational 
attainment and iron scores) were assessed using a Jonckeere-Terpstra test, or the exact 
equivalent. Continuous measures were summarized as medians and interquartile ranges with 
differences in group distributions assessed using a Wilcoxon rank sum test (for comparison of 
two groups) or a Kruskal-Wallis test (for comparison of more than two groups). To assess if 
changes in lipid profile measures significantly differed from baseline, a Wilcoxon sign rank test 
was used. Linear regression was conducted to compare the trend in the changes in lipid profile 
measures distributions across categories of the amount of PEG-IFN taken. Compared to baseline, 
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changes in dyslipidemic status during and after treatment were assessed using the McNemar’s 
test of homogeneity. For all statistical tests, a p-value of <0.05 was considered to be statistically 
significant. Generalized estimating equation (GEE) models were employed with each lipid 
profile measure as the outcome over time reflecting changes during and after treatment, 
compared to its baseline value. To account for extreme outliers of dependent variables, TG, 
HDLc, and TC levels were transformed using the natural logarithm (ln).   
Baseline characteristics were included in GEE models with three time-dependent or post-
baseline covariates: participant body weight, the amount of PEG-IFN taken, and 6 month 
virological response. Variable reduction was achieved using a stepwise approach. As needed, 
continuous covariates were transformed in models to improve linearity of associations, and 
predictors were centered about their means. All analyses were conducted using Statistical 
Analysis Software (SAS) Version 9 (Carey, NC) or STATA Version 9 (College Station, TX).  
6.4 RESULTS 
Characteristics of the study cohort are summarized by race in Table 6-1. AAs tended to be older, 
have higher BMIs and lower ALT levels than CAs (p<0.05 for all). In addition, a higher 
proportion of AAs were diabetic, hypertensive, and infected with genotype 1b compared to CAs 
(p<0.05 for all). No significant racial differences (p>0.05 for all) in histological measures were 
found. Among lipid profile measures, racial differences at baseline were only found for LDLc, 
which was significantly lower in AAs than CAs (109 versus 119 mg/dL, p=0.02).  
Compared to pretreatment, there were significant changes in the serum lipid profile 
during therapy and after therapy significant changes were limited to 6 month virological 
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responders. (Figure 6-1) During the first 24 weeks of therapy, TG levels increased significantly, 
in contrast to LDLc, HDLc, and TC, which declined (p<0.0001 for all). During follow up and 
among participants who underwent a 48 week course of therapy (6 month virological 
responders), TG levels remained significantly higher than pretreatment (p<0.05), as did LDLc 
(p<0.0001) and TC levels (p<0.0001). During follow up among 6 month non-responders, there 
were no significant changes in the lipid profile compared to pretreatment, although the lack of 
statistical significance may be related to the smaller sample size of this group (n=62) than 6 
month virological responders (n=177). During 24 weeks of treatment, 61% of participants who 
were not dyslipidemic at baseline became newly classified as dyslipidemic, a significant change 
which occurred within both races. (Table 6-2) Post-treatment, there was no significant change in 
the percentage of the cohort classified as dyslipidemic compared to baseline.    
Though 84% of participants took at least 90% of the maximum dose of PEG-IFN for the 
initial 24 weeks of therapy, as the percentage of the maximum dose of PEG-IFN taken (<90%, 
90% to 99.9%, and 100%) increased, so did the declines in LDLc and TC from baseline (p for 
trend=0.004 and 0.02, respectively). (Figure 6-2) Changes in the serum lipid profile differed 
significantly by race during the first 6 months of therapy. (Figure 6-3) In particular, increases in 
TG and the decreases in LDLc levels were greater among CAs than AAs (p=0.003 and 
p<0.0001, respectively). The patterns of decreases in TC levels by race were similar to LDLc 
changes, although the differences were not statistically significant (p=0.054). In GEE models 
evaluating the relationship between race and lipid profile measures during 24 weeks of therapy, 
the interaction between race and time was statistically significant for TG, LDLc, and TC (p<0.05 
for all), adjusting for the proportion of PEG-IFN taken and body weight changes. (Table 6-3) 
Interpreted as race-specific coefficients, compared to AAs, CAs had significantly larger 
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increases in the natural log of TG (βAA=0.22, p<0.0001; βCA=0.44, p<0.001) and larger decreases 
in LDLc (βAA=-13.9, p=0.005; βCA=-24.7, p<0.0001) and TC (βAA=-0.08, p<0.0001; βCA=-0.13, 
p<0.0001) from baseline.  
In multivariable assessments adjusting for the amount of PEG-IFN taken, weight change, 
6 month virological response, and race, interaction between race and time remained statistically 
significant for LDLc and TC (p<0.001 for both) indicating that the change in these lipid profile 
measures differed significantly by race. (Table 6-4) The declines in LDLc and TC were 
significantly different from zero in both race groups (p<0.01 for all), with the declines being 
greater among CAs than AAs (LDLc: βCA=-24.1 and βAA=-8.4; natural log of TC: βCA=-0.13 and 
βAA=-0.07). Compared to females, males had a greater increases TG (β=0.12, p=0.02) and 
declines HDLc (β=-0.21, p<0.001) and TC (β=-0.05, p=0.03) on the natural log scale. 
Histological measures of liver disease were also significantly associated with the natural logs of 
TG and HDLc (fat score β=0.20, p=0.004 and β=-0.07, p=0.01, respectively), LDLc (HAI 
inflammation score), and TC (Ishak fibrosis score β=-0.02, p=0.03).  
6.5 DISCUSSION 
During 24 weeks of combination PEG-IFN and ribavirin therapy there were significant changes 
in TG, LDLc, HDLc, and TC from baseline. Compared to pre-treatment levels, there were also 
post-treatment changes, but they were limited to 6 month virological responders who underwent 
a 48 week course of treatment. During the first 24 weeks of therapy, greater amounts of PEG-
IFN taken were associated with significantly larger declines in LDLc and TC from pretreatment 
levels. Lastly, the significant increases in TG and declines in LDLc and TC during the first 24 
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weeks of treatment significantly differed by race and remained statistically significant after 
accounting for the amount of PEG-IFN taken and body weight changes.  
Few studies have assessed changes in the serum lipid profile during and after therapy for 
chronic HCV and findings are inconsistent. The significant increase in TG levels during therapy 
found here is consistent with other study findings.52, 53 However, the increase in TC post-therapy 
compared to pretreatment is consistent with one study,52 but not another.53 Note, thought, that 
these studies reported increases in TC during therapy, in contrast to the current study which 
found significant declines in TC during treatment. In another study, TC levels did not 
significantly change during or after therapy compared to pretreatment.54 The different findings 
across studies suggest the need for further investigation but may be due to the disparate treatment 
regimens, HCV genotypes with which participants were infected, and other participant 
characteristics. 
The current study is the first epidemiologic study to report an association between 
declines in LDLc and TC during 24 weeks of therapy and the amount of PEG-IFN taken. Recent 
in vitro work found that the expression scavenger receptor B-1, a lipoprotein receptor for high 
density lipoprotein, decreased with interferon exposure.72 These findings suggest that antiviral 
therapy may change lipoprotein receptor expression, which may in turn impact circulating 
lipoprotein levels and the serum lipid profile. HCV eradication may likewise result in resolution 
of liver disease and subsequent changes in lipid and lipoprotein metabolism. The significant 
racial differences in the changes in TG, LDLc, and TC during the first 6 months of therapy is 
another novel finding and warrants further evaluation given the racial disparity in virological 
response between AAs and CAs found in other studies.10-12  
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This study also assessed dyslipidemia, a risk factor for cardiovascular disease (CVD) for 
which incident cases arose during treatment.  However, the prevalence post-treatment did not 
differ significantly from baseline suggesting that although the CVD risk profile may increase in 
association with antiviral therapy, the increased risk may be transient.  However, CVD risk based 
on other measures not accounted for in this study, such as inflammatory, atherosclerotic, and 
arteriolsclerotic assessments, may yield more information to better characterize the impact of 
antiviral therapy to CVD. Prospective studies utilizing these measures are needed.    
This study has limitations, which may influence the results. For instance, numerous side-
effects are associated with PEG-IFN therapy including gastrointestinal disturbances, such as 
nausea, weight loss, and anorexia.9 Although body weight changes during and after treatment 
were controlled for in the analysis, it is possible that modifications to dietary intake may have 
occurred, resulting in significant changes in the serum lipid profile measures. Food intake 
assessments were not included in the Virahep-C study design. Another limitation was the use of 
stepwise modeling for variable selection (refer sections 5.5 and 8.1 for discussion of limitations). 
This study demonstrates that combination therapy is associated with significant changes 
in the serum lipid profile and these findings are potentially relevant to antiviral mechanisms of 
PEG-IFN and ribavirin for the treatment of chronic HCV infection. This study also found that 
during 24 weeks of therapy, the changes in the serum lipid profile differed by race. Further 
evaluation of the relationship between serum lipid profile measures and treatment efficacy is 
warranted to determine if the lipid profile explains any of the racial difference in treatment 
response between AAs and CAs.  
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6.6 TABLES 
Table 6-1. Cohort characteristics  
Feature* AA (n=135) CA (n=153) Overall (n=288) p 
Demographics     
Age (years) 49 (46,52) 47 (42,51) 48 (44,52) 0.03 
% Male 89 (65.9) 100 (65.4) 189 (65.5) 0.92 
Clinical features     
BMI (m=4) 28.8 (26.4,33.4) 27.9 (24.9,31.5) 28.4 (25.3,32.3) 0.007 
%Diabetic 21 (15.6) 5 (3.3) 26 (9.0) 0.0003 
%Hypertensive 57 (42.2) 30 (19.6) 87 (30.2) <0.0001 
Viral characteristics     
Log10 HCV level (m=1) 6.5 (5.6,6.7) 6.5 (5.7,6.8) 6.5 (5.6,6.8) 0.35 
HCV genotypea    0.004 
    %1, NOS 6 (4.4) 14 (9.2) 20 (6.9) 0.12 
    %1a 68 (50.4) 86 (56.2) 154 (53.5) 0.32 
    %1a/b 1 (0.7) 9 (5.9) 10 (3.5) 0.02 
    %1b 60 (44.4) 44 (28.8) 104 (36.1) 0.006 
Liver disease indicators     
ALT (IU/L) 63 (41,90) 76 (52,140) 71 (46.5,110) 0.0002 
AST (IU/L) 54 (36,73) 53 (38,89) 54 (37,80.5) 0.11 
Histological measures     
Ishak fibrosis score 2 (1,3) 2 (1,3) 2 (1,3) 0.98 
%Ishak fibrosis score > 3 52 (38.5) 60 (39.2) 112 (38.9) 0.90 
Fat score  0.5 (0,1) 0.5 (0,1) 0.5 (0,1) 0.16 
%Steatosis (>5% present)  80 (59.3) 101 (66.0) 181 (62.9) 0.24 
Total HAI inflammation  8 (7,10) 9 (6,11) 8 (6,11) 0.90 
Iron score (m=28)    0.10 
   0 57 (47.5) 81 (57.9) 138 (53.1)  
   1 52 (43.3) 49 (35.0) 101 (38.9)  
   2 11 (9.2) 10 (7.1) 21 (8.1)  
Baseline serum lipid measures     
TG (mg/dL) 105 (74,165) 97 (74,137) 100 (74,146.5) 0.13 
LDLc (mg/dL) 108.8 (83.3,133.1) 118.7 (93.1,141.9) 115.5 (88.1,137.5) 0.02 
HDLc (mg/dL) 42.7 (32.6,54.2) 40.7 (33.7,50.7) 41.0 (33.5,52.1) 0.34 
TC (mg/dL) 183 (155,204) 185 (160,209) 185 (156,206) 0.22 
m=missing 
*Each categorical variable is summarized as n (%) with p-values corresponding to a Pearson’s chi-square test 
(nominal variables) or the Jonckheere-Terpstra test (ordinal variables) or exact equivalents, where appropriate; 
each continuous variable is summarized as a median (interquartile range) with a p-value corresponding to a 
Wilcoxon rank sum test.  
For features with two or more categories, the global p-value is listed in the first row of the feature. Where the 
global p-value is <0.05, p-values correspond to Pearson’s chi-square with comparisons as follows: 
aEach genotype compared to other categories combined
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Table 6-2. Dyslipidemic status during and after therapy compared to baseline 
Tx week 24  
status 
F-up week 24  
status (R) 
F-up week 24 
 status (NR) Baseline 
status + – + – + – 
Both races       
      + 167 (66.0) 11 (4.4) 113 (63.8) 19 (10.7) 31 (50.0) 10 (16.1) 
      – 46 (18.2) 29 (11.5) 19 (10.7) 26 (14.7) 5 (8.1) 16 (25.8) 
      p-value <0.0001 1.0 0.20 
CAs       
      + 94 (68.6) 6 (4.4) 76 (65.5) 12 (10.3) 7 (46.7) 1 (6.7) 
      – 25 (18.3) 12 (8.8) 13 (11.2) 15 (12.9) 1 (6.7) 6 (40.0) 
      p-value 0.006 0.84 1.0 
AAs       
      + 73 (62.9) 5 (4.3) 37 (60.7) 7 (11.5) 24 (51.1) 9 (19.2) 
      – 21 (18.1) 17 (14.7) 6 (9.8) 11 (18.0) 4 (8.5) 10 (21.3) 
      p-value 0.002 0.78 0.17 
Tx=dyslipidemic status after 24 weeks of treatment 
F-up=dyslipidemic status 24 weeks after stopping treatment 
R=treatment 24 virological responders (underwent 48 weeks of treatment) 
NR=treatment week 24 virological non-responders (underwent only 24 weeks of treatment) 
p=McNemar’s test for homogeneity (p<0.05 reflects significant change in dyslipidemic status) 
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Table 6-3. Adjusted* GEE models 
Lipid profile measure 
ln(TG) LDLc ln(HDLc) ln(TC) 
Predictors β (95%CI) p β (95%CI) p β (95%CI) p β (95%CI) p 
 All participants: baseline through treatment week 24(week 24) 
Week 24` NA NA NA NA -0.22 (-0.25,-0.19) <0.0001 NA NA
AA** 0.10 (-0.03,0.22) 0.12 -7.3 (-15.6,1.0) 0.08 0.05 (-0.02,0.11) 0.16 -0.01 (-0.06,0.03) 0.63 
Race X time⎯  0.01  <0.0001  0.71  0.02 
 CA: week 24` 0.40 (0.31,0.49) <0.0001 -24.7 (-29.5,-20.0) <0.0001   -0.13 (-0.16,0.10) <0.0001 
 AA: week 24` 0.22 (0.13,0.32) <0.0001 -8.4 (-14.2,-2.5) 0.005   -0.08 (-0.11,-0.05) <0.0001 
 Treatment week 24 virological responders only: baseline through follow-up week 24 (week 72) 
Global time^  <0.0001  <0.0001  <0.0001  <0.0001 
Week 24` 0.39 (0.31,0.47) <0.0001 NA NA -0.22 (-0.25,-0.19) <0.0001 NA NA
Week 72~ 0.08 (0.02,0.15) 0.02 NA NA 0.01 (-0.02,0.04) 0.55 NA NA
AA** -0.10 (-0.24,0.03) 0.14 0.09 (-11.1,11.3) 0.99 0.07 (-0.003,0.15) 0.06 0.01 (-0.05,0.07) 0.79 
Race X time⎯  0.27  0.02  0.71  0.03 
 CA: week 24`   -26.4 (-31.8,-21.0) <0.0001   -0.13 (-0.17,-0.10) <0.0001 
 AA: week 24`   -13.9 (-22.7,-5.1) 0.002   -0.09 (-0.13,-0.04) <0.0001 
 CA: week 72~   10.2 (5.7,14.7) <0.0001   0.07 (0.04,0.09) <0.0001 
 AA: week 72~   6.4 (-0.6,13.5) 0.07   0.04 (0.004,0.07) 0.03 
 Treatment week 24 virological non-responders  only: baseline through follow-up week 24 (week 48) 
Global time^  0.01  0.22  <0.0001  0.0006 
Week 24` 0.19 (0.06,0.32) 0.004 -4.7 (-10.3,0.8) 0.10 -0.22 (-0.28,-0.16) <0.0001 -0.07 (-0.10,-0.03) <0.0001 
Week 48~ 0.03 (-0.08,0.13) 0.62 -2.1 (-7.8,3.5) 0.46 0.02 (-0.04,0.07) 0.50 -0.01 (-0.04,0.03) 0.65 
AA** 0.11 (-0.10,0.31) 0.31 3.0 (-11.7,17.6) 0.69 0.01 (-0.12,0.14) 0.91 0.04 (-0.05,0.13) 0.42 
Race X time⎯  0.81  0.44  0.24  0.81 
*Adjusted for the proportion of PEG-IFN taken, body weight change (not shown), and race (regardless of statistical significance) 
**CA reference 
^p-value indicates overall test for time only 
`Indicates treatment week 24 assessment (on-treatment change from baseline) 
~Indicates follow-up week 24 assessment (post-treatment change from baseline) 
⎯ Non-statistically significant race/time interactions (p>0.05) were not included in models 
NA=Not applicable due to statistically significant race/time interaction (refer to race and time specific coefficients)
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Table 6-4. Multivariable GEE models  
ln(TG) LDLc ln(HDLc) ln(TC) 
Baseline characteristic β  (95%CI) p β (95%CI) p β (95%CI) p β  (95%CI) p 
AA race* 0.01 (-0.11,0.12) 0.92 -0.5 (-9.3,8.3) 0.91 0.02 (-0.04,0.09) 0.48 0.01 (-0.04,0.06) 0.75 
Global test of time  <0.001  0.007  <0.001  <0.001 
Tx week 24 0.34 (0.27,0.41) <0.001 NA NA -0.22 (-0.25,-0.19) <0.001 NA NA 
F-up  week 24 0.07 (0.01,0.13) 0.02 NA NA 0.01 (-0.01,0.04) 0.36 NA NA 
Race X time–  0.10  <0.001  0.96  <0.001 
    CA: Tx week 24   -24.1 (-29.0,-19.2) <0.001   -0.13 (-0.15,-0.10) <0.001 
    AA: Tx week 24   -8.4 (-14.1,-2.6) 0.004   -0.07 (-0.11,-0.04) <0.001 
    CA: F-up week 24   9.3 (5.0,13.5) <0.001   0.06 (0.04,0.09) <0.001 
    AA: F-up week 24   2.1 (-2.8,7.0) 0.40   0.02 (-0.01,0.04) 0.23 
Male gender** 0.12 (0.02,0.22) 0.02   -0.21 (-0.28,-0.14) <0.001 -0.05 (-0.10,-0.004) 0.03 
Ishak fibrosis score       -0.02 (-0.03,-0.002) 0.03 
Fat score 0.20 (0.12,0.27) 0.004   -0.07 (-0.13,-0.02) 0.01   
Total HAI inflammation  ^   -55.0 (-108.7,-1.3) 0.045     
NOTE: Models were adjusted for the proportion of PEG taken, body weight change, 6 month responder status (not shown), and race regardless of statistical 
significance.  
NA=Not applicable due to statistically significant race/time interaction (refer to race and time specific coefficients) 
Transformations as noted: ` = natural log; ^  = 1 – reciprocal.  
-Non-statistically significant race/time interactions (p>0.05) were not included in models 
*CA reference 
**Female reference 
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Table 6-5. Supplement 1a: Changes in TG during and after therapy by categorical features 
Tx – BL (n=253) F-up – BL (R) (n=177) F-up – BL (NR) (n=62) 
Feature n Median (IQR) p* n Median (IQR) p* n Median (IQR) p* 
Demographics          
Race   0.005   0.50   0.97 
   AA race 116 21 (-10.5,60.5)  61 2 (-19,33)  47 9 (-28,40)  
   CA race 137 40 (8,91)  116 10 (-19,42)  15 9 (-25,30)  
Gender      0.96   0.43 
   Male 167 24 (-12,87) 0.16 113 7 (-25,43)  45 10 (-11,33)  
   Female 86 39 (8,83)  64 9 (-13,28.5)  17 -10 (-32,30)  
Health insurance   0.002   0.18   0.68 
   Uninsured 45 12 (-21,49)  30 8.5 (-31,42)  8 20.5 (-12,36)  
   Public 54 21.5 (-23,56)  37 -9 (-21,33)  11 9 (-11,40)  
   Private 149 41 (5,91)  106 13 (-9,40)  43 1 (-31,32)  
Educational attainment    0.06   0.67   0.28 
     <High school 43 17 (-15,59)  25 7 (-17,33)  12 9.5 (-30.5,43)  
     High school degree 61 37 (-9,85)  39 8 (-28,22)  15 21 (-24,68)  
     Some college 83 28 (-7,85)  58 10 (-17,44)  20 -1 (-16.5,31.5)  
     >College degree 59 53 (14,88)  49 15 (-16,40)  14 -4.5 (-35,11)  
Employed 164 40 (3,90.5) 0.02 114 8 (-13,37) 0.34 44 6 (-29.5,32.5) 0.75 
   Unemployed 86 22.5 (-15,54)  60 8.5 (-31,44.5)  18 10 (-11,40)  
Health risk behaviors          
Current smoker 94 25 (-15,82) 0.29 69 5 (-19,33) 0.14 22 20.5 (-11,42) 0.09 
   Non-smoker 154 32.5 (4,86)  104 12.5 (-16,42)  40 -1 (-29.5,29.0)  
>2 alcoholic drinks/week 48 23 (-7.5,68.5) 0.35 33 2 (-25,32) 0.39 15 20 (-47,32) 0.83 
   <2 alcoholic drinks/week 199 35 (1,86)  139 12 (-16,41)  47 9 (-24,40)  
General clinical features          
Diabetic 23 17 (-12,98) 0.79 11 2 (-53,58) 0.93 11 10 (-11,19) 0.85 
   Non-diabetic 230 30.5 (1,83)  166 8 (-19,38)  51 3 (-28,40)  
Hypertensive 73 25 (-7,66) 0.13 44 -2 (-25.5,33.5) 0.36 28 3.5 (-47.5,20.5) 0.10 
   Non-hypertensive 180 33 (0.5,87.5)  133 9 (-17,42)  34 10 (-11,40)  
Viral characteristics          
HCV genotype   0.45   0.19   0.16 
    1, NOS 16 49.5 (-10.5,95.5)  15 -3 (-43,17)  3 -97 (-110,-25)  
    1a 135 28 (1,73)  93 9 (-12,44)  34 9.5 (-24,34)  
    1b 92 26.5 (-7,82.5)  61 4 (-28,33)  24 19 (8.5,35.5)  
    1a/1b 10 87.5 (-24,158)  8 33.5 (-35,69.5)  1 9 (NA,NA)  
Liver disease indicators   0.046   0.90   0.96 
Ishak fibrosis score > 3 102 21.5 (-7,54)  67 7 (-16,38)  30 10.5 (-28,33)  
   <3 151 38 (3,91)  110 9 (26,40)  32 2 (-23.5,36)  
Steatosis (>5% present) 160 32.5 (-2,85) 0.77 110 8 (-19,40) 0.89 39 -5 (-47,31) 0.045 
  No steatosis 93 26 (3,79)  67 9 (-21,38)  23 10 (-4,49)  
Iron score   0.0006   0.49   0.33 
   0 123 40 (5,88)  90 10 (-17,40)  25 3 (-22,27)  
   1 86 12 (-24,43)  56 5.5 (-18,41)  26 3.5 (-25,40)  
   2 19 49 (-21,119)  14 -0.5 (-57,17)  5 31 (31,32)  
 Tx=treatment week 24 (during treatment) ; BL=baseline (pre-treatment); F-up=Follow-up week 24 (post-treatment) 
 *p-value corresponds to the Wilcoxon rank sum or Kruskal-Wallis test. 
 R=6 month virological responders 
NR=6 month nonresponders 
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Table 6-6. Supplement 1b: Changes in LDLc during and after therapy by categorical features 
Tx – BL (n=253) F-up – BL (R) (n=177) F-up – BL (NR) (n=62) 
Feature n Median (IQR) p* n Median (IQR) p* n Median (IQR) p* 
Demographics          
Race   <0.001   0.33   0.51 
   AA race 116 -7.4 (-24.1,-7.6)  61 4.5 (12.2,22.2)  47 -3.9 (-17.4,13)  
   CA race 137 -20.4 (-44.5,-6.5)  116 9.4 (-7.7,28.3)  15 1.7 (-9.5,17.9)  
Gender   0.11   0.56   0.40 
   Male 167 -17.2 (-38.4,-2.1)  113 7.2 (-9.7,24.5)  45 -4.1 (-17.4,7.8)  
   Female 86 -11.5 (-32.0,5.0)  64 7.7 (-7.0,27.0)  17 1.1 (-9.5,16.7)  
Health insurance   0.18   0.61   0.20 
   Uninsured 45 -7.5 (-28.0,8.9)  30 12.9 (-2.9,24.0)  8 -7.7 (-23.0,2.2)  
   Public 54 -17.3 (-35.0,0.0)  37 7.5 (-9.2,36.1)  11 -6.1 (-24.7,7.8)  
   Private 149 -15.9 (-41.2,-2.1)  106 5.0 (-9.4,24.5)  43 1.1 (-13.8,17.9)  
Educational attainment    0.74   0.83   0.10 
     <High school 43 -20.4 (-38.4,-7.4)  25 8.4 (-9.4,19.5)  12 2.3 (-26.1,14.3)  
     High school degree 61 -12.2 (-33.4,1.4)  39 6.8 (-9.7,23.3)  15 -12.5 (-27.3,-4.5)  
     Some college 83 -15.0 (-37.0,2.1)  58 6.9 (-7.5,23.0)  20 1.2 (-11.9,19.1)  
     >College degree 59 -13.3 (-41.2,6.0)  49 9.8 (-8.4,35.0)  14 1.6 (-3.9,13.0)  
Employed 164 -14.2 (-35.1,2.3) 0.36 114 7.6 (-7.1,28.3) 0.46 44 -1 (-16.7,17.3) 0.57 
   Unemployed 86 -18.1 (-42.8,-2.1)  60 5.5 (-10.7,23.2)  18 -5.2 (-15.1,7.8)  
Health risk behaviors          
Current smoker 94 -16.9 (-37.5,-3.8) 0.25 69 9.7 (-7.5,36.1) 0.22 22 -5.7 (-27.4,13.0) 0.29 
   Non-smoker 154 -14.2 (-37.0, 3.4)  104 5.3 (-9.0,24.0)  40 -0.8 (-9.8,11.6)  
>2 alcoholic drinks/week 48 -12.8 (-27.3,5.6) 0.22 33 3.7 (-9.7,23.3) 0.61 15 -4.6 (-26.7,17.7) 0.57 
<2 alcoholic drinks/week 199 -15.9 (-40.9,1.1)  139 7.6 (-9.0,28.3)  47 -2.7 (-15.1,13.0)  
General clinical features          
Diabetic 23 -8.5 (-22.5,2.3) 0.15 11 16.8 (-1.7,47.2) 0.23 11 0.7 (-5.3,20.7) 0.35 
   Non-diabetic 230 -15.1 (-38.4,1.1)  166 6.7 (-9.2,24.5)  51 -4.1 (-17.4,13.0)  
Hypertensive 73 -8.5 (-26.1, 2.3) 0.07 44 16.0 (4.0,33.0) 0.02 28 -1.8 (-18.0,8.5) 0.83 
   Non-hypertensive 180 -17.6 (-42.1, 0.1)  133 3.6 (-10.5,24.2)  34 -3.2 (-15.1,16.9)  
Viral characteristics          
HCV genotype   0.06   0.42   0.18 
    1, NOS 16 -18.1 (-59,-9.4)  15 17.1 (-3.5,22.3)  3 17.9 (5.5,31.4)  
    1a 135 -15.9 (-36.9,-0.3)  93 3.7 (-10.5,28.3)  34 -0.4 (-12.5,16.9)  
    1b 92 -13.0 (-29.0, 4.6)  61 8.5 (-2.4,24.5)  24 -4.9 (-18.0,1.6)  
    1a/1b 10 -41.7 (-60.8,-7.7)  8 22.3 (-0.6,35.1)  1 -9.5 (NA,NA)  
Liver disease indicators          
Ishak fibrosis score > 3 102 -14.3 (-29.4,-4.1) 0.70 67 10.4 (-1.1,33.9) 0.07 30 -2.8 (-18.8,7.8) 0.82 
   <3 151 -17.2 (-42.1,3.7)  110 2.1 (-9.4,24.0)  32 -3.3 (-13.2,17.3)  
Steatosis (>5% present) 160 -17.4 (-37.0,-2.3) 0.25 110 7.6 (-8.4,25.3) 0.81 39 0.3 (-18.5,17.7) 0.65 
  No steatosis 93 -9.5 (-38.1,5.3)  67 5.4 (-9.4,28.3)  23 -4.5 (-15.1,7.8)  
Iron score   0.87   0.46   0.84 
   0 123 -16.5 (-41.2,2.1)  90 7.1 (-9.4,24.5)  25 -2.7 (-13.8,9.2)  
   1 86 -14.6 (-38.8,0.0)  56 9.8 (-5.5,29.8)  26 0.9 (-17.4,17.9)  
   2 19 -14.6 (-29.9,-5.6)  14 -1.8 (-7.1,17.1)  5 -4.1 (-15.1,3.9)  
  Tx=treatment week 24 (during treatment) ; BL=baseline (pre-treatment); F-up=Follow-up week 24 (post-treatment) 
  *p-value corresponds to the Wilcoxon rank sum or Kruskal-Wallis test.  
  R=6 month virological responders  
NR=6 month nonresponders 
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Table 6-7. Supplement 1c: Changes in HDLc during and after therapy by categorical features 
Tx – BL (n=253) F-up – BL (R) (n=177) F-up – BL (NR) (n=62) 
Feature n Median (IQR) p* n Median (IQR) p* n Median (IQR) p* 
Demographics          
Race   0.65   0.70   0.35 
   AA race 116 -8.3 (-14.2,-2.7)  61 -0.1 (-3.9,5.2)  47 0.8 (-7.6,6.9)  
   CA race 137 -8.0 (-13.9,-3.5)  116 1.1 (-5.6,6.9)  15 -3.1 (-7.1,3.4)  
Gender   0.004   0.16  0.15  
   Male 167 -7.2 (-12.8,-2.8)  113 -1.5 (-3.9,5.6)  45 -1.0 (-7.1,3.4)  
   Female 86 -10.9 (-19.6,-4.3)  64 -1.7 (-6.9,6.1)  17 3.9 (-5.0,12.6)  
Health insurance   0.66   0.94   0.43 
   Uninsured 45 -8.4 (-16.2,-4.5)  30 -0.2 (-5.0,8.2)  8 3.0 (-1.5,9.2)  
   Public 54 -8.1 (-12.9,-2.4)  37 2.7 (-5.2,8.2)  11 -1.7 (-8.9,1.9)  
   Private 149 -7.8 (-14.2,-3.2)  106 0.5 (-5.6,5.1)  43 -0.9 (-7.6,6.9)  
Educational attainment    0.04   0.50   0.46 
     <High school 43 -5.8 (-12.1,-1.8)  25 0.7 (-2.9,4.0)  12 1.2 (-3.4,6.1)  
     High school degree 61 -7.6 (-12.1,-0.3)  39 2.7 (-3.8,9.5)  15 -5.0 (-8.9,3.2)  
     Some college 83 -10.4 (-16.3,-5.3)  58 -0.5 (-6.7,5.3)  20 0.9 (-1.6,10.8)  
     >College degree 59 -8.8 (-14.2,-4.2)  49 0.6 (-5.2,5.1)  14 0 (-7.2,6.4)  
Employed 164 -8.1 (-13.7,-3.3) 0.80 114 0.8 (-5.2,6.3) 0.71 44 -0.1 (-7.4,7.3) 0.86 
   Unemployed 86 -8.1 (-15.4,-2.8)  60 1.1 (-6.5,5.1)  18 0.3 (-3.6,1.9)  
Health risk behaviors          
Current smoker 94 -7.3 (-14.1,-1.2) 0.0501 69 2.8 (-2.9,8.2) 0.006 22 0.6 (-7.1,6.2) 0.96 
   Non-smoker 154 -9.1 (-14.6,-4.3)  104 -1.7 (-6.8,4.7)  40 -1.0 (-6.8,6.7)  
>2 alcoholic drinks/week 48 -8.8 (-17.5,-4.8) 0.30 33 2.0 (-3.7,7.4) 0.33 15 3.2 (-4.9,6.9) 0.42 
<2 alcoholic drinks/week 199 -7.8 (-14.1,-3.0)  139 0.1 (-5.9,5.2)  47 -0.9 (-7.9,6.4)  
General clinical features          
Diabetic 23 -6.3 (-12.8,-1.6) 0.31 11 1.5 (-8.3,8.0) 0.83 11 0.9 (-7.9,5.9) 0.98 
   Non-diabetic 230 -8.1 (-14.2,-3.3)  166 0.8 (-5.5,5.6)  51 -0.9 (-7.1,6.9)  
Hypertensive 73 -8.4 (-13.9,-3.6) 0.81 44 0.0 (-5.1,6.3) 0.87 28 1.3 (-2.5,7.1) 0.13 
   Non-hypertensive 180 -8.0 (-14.2,-2.8)  133 0.9 (-5.9,5.9)  34 -1.9 (-7.6,3.9)  
Viral characteristics          
HCV genotype   0.35   0.12   0.25 
    1, NOS 16 -7.7 (-10.5,-3.8)  15 1.4 (-5.1,6.3)  3 -1.4 (-4.9,0.9)  
    1a 135 -7.7 (-12.9,-3.0)  93 1.8 (-5.1,7.8)  34 -0.4 (-8.0,6.9)  
    1b 92 -9.4 (-14.8,-3.5)  61 -1.9 (-7.7,4.2)  24 1.0 (-4.5,6.7)  
    1a/1b 10 -4.7 (-15.0,3.7)  8 3.2 (-1.4,7.3)  1 -23.0 (NA,NA)  
Liver disease indicators          
Ishak fibrosis score > 3 102 -7.8 (-14.2,-2.8) 0.43 67 2.4 (-6.3,7.4) 0.72 30 1.4 (-3.6,10.4) 0.15 
   <3 151 -8.5 (-14.2,-3.3)  110 0.3 (-5.1,4.9)  32 -1.2 (-7.4,3.7)  
Steatosis (>5% present) 160 -8.1 (-13.7,-3.4) 0.996 110 -0.1 (-6.0,5.1) 0.23 39 0.9 (-4.9,6.9) 0.19 
  No steatosis 93 -7.8 (-16.1,-2.4)  67 2.1 (-5.1,8.2)  23 -2.1 (-8.9,3.4)  
Iron score   0.06   0.38   0.60 
   0 123 -8.8 (-14.2,-4.3)  90 -0.9 (-6.1,5.1)  25 0.8 (-5.9,3.4)  
   1 86 -7.0 (-13.9,-0.5)  56 2.8 (-5.2,8.2)  26 -1.0 (-8.0,7.7)  
   2 19 -6.8 (-11.1,-2.0)  14 0.1 (-3.9,3.9)  5 -1.3 (-8.9,-0.9)  
 Tx=treatment week 24 (during treatment) ; BL=baseline (pre-treatment); F-up=Follow-up week 24 (post-treatment) 
 *p-value corresponds to the Wilcoxon rank sum or Kruskal-Wallis test. 
 R=6 month virological responders 
NR=6 month nonresponders 
  
  65
Table 6-8. Supplement 1d: Changes in TC during and after therapy by categorical features 
Tx – BL (n=253) F-up – BL (R) (n=177) F-up – BL (NR) (n=62) 
Feature n Median (IQR) p* n Median (IQR) p* n Median (IQR) p* 
Demographics          
Race   0.054   0.33   0.60 
   AA race 116 -13.5 (-30,2.5)  61 7 (-7,19)  47 -6 (-19,16)  
   CA race 137 -18 (-36,-4)  116 9.5 (-7,30.5)  15 5 (-20,13)  
Gender   0.23   0.94   0.10 
   Male 167 -18 (-34,-3)  113 9 (-6,23)  45 -8 (-19,8)  
   Female 86 -14 (-30.0,7)  64 6 (-8.5,28.5)  17 7 (-1,13)  
Health insurance   0.80   0.94   0.67 
   Uninsured 45 -20 (-36,-2)  30 9 (0,21)  8 -1 (-25,6)  
   Public 54 -20.5 (-38,-5)  37 3 (-7,33)  11 -6 (-26,28)  
   Private 149 -17 (-30,-1)  106 9 (-8,25)  43 -5 (-18,17)  
Educational attainment    0.16   0.90   0.43 
     <High school 43 -21 (-35,-11)  25 8 (-6,15)  12 0 (-25,15.5)  
     High school degree 61 -14 (-27,2)  39 7 (-2,24)  15 -16 (-26,13)  
     Some college 83 -21 (-38,-2)  58 8.5 (-4,21)  20 0 (-13,21.5)  
     >College degree 59 -15 (-27,7)  49 13 (-9,37)  14 2.5 (-15,8)  
Employed 164 -14 (-28.5,2) 0.008 114 11 (0,30) 0.04 44 -7 (-19,18) 0.89 
   Unemployed 86 -25.5 (-43,-5)  60 2.5 (-12.5,22)  18 2.5 (-19,11)  
Health risk behaviors          
Current smoker 94 -19 (-32,-4) 0.36 69 13 (-2,33) 0.24 22 -6 (-22,13) 0.58 
   Non-smoker 154 -15 (-33,2)  104 7.5 (-8.5,23.7)  40 -0.5 (-15.5,14.5)  
>2 alcoholic drinks/week 48 -19 (-29,-7) 0.95 33 5 (-7,24) 0.69 15 -5 (-28,8) 0.44 
   <2 alcoholic drinks/week 199 -16 (-35,0)  139 9 (-7,30)  47 0 (-19,17)  
General clinical features          
Diabetic 23 -13 (-25,10) 0.09 11 3 (0,53) 0.54 11 6 (-13,19) 0.37 
   Non-diabetic 230 -17 (-35,-2)  166 9 (-8,25)  51 -7 (-19,13)  
Hypertensive 73 -17 (-30,2) 0.67 44 13 (1.5,34.5) 0.15 28 -3 (-18,12.5) 0.72 
   Non-hypertensive 180 -15 (-35,-1)  133 7 (-9,24)  34 -3 (-19,13)  
Viral characteristics          
HCV genotype   0.39   0.57   0.40 
    1, NOS 16 -20 (-50.5,-7.5)  15 7 (-6,20)  3 8 (-13,8)  
    1a 135 -14 (-32,1)  93 9 (-11,32)  34 3 (-19,17)  
    1b 92 -17.5 (-33.5,2)  61 7 (-3,20)  24 19 (-8.5,35.5)  
    1a/1b 10 -25 (-46,-16)  8 23.5 (8.5,44.5)  1 31 (NA, NA)  
Liver disease indicators   0.98   0.055   0.99 
Ishak fibrosis score > 3 102 -17 (-32,-1)  67 14 (2,37)  30 -1 (-20,13)  
   <3 151 -17 (-36,2)  110 5 (-9,23)  32 -5.5 (-17,14.5)  
Steatosis (>5% present) 160 -19 (-35,-1.5) 0.18 110 8.5 (-7,25) 0.999 39 -1 (-20,11) 0.35 
  No steatosis 93 -14 (-29,0)  67 9 (-8,30)  23 -6 (-16,24)  
Iron score   0.86   0.27   0.95 
   0 123 -19 (-30,-2)  90 9 (-7,24)  25 -1 (-15,13)  
   1 86 -16 (-36,0)  56 9 (-3.5,33.5)  26 0.5 (-22,19)  
   2 19 -11 (-34,0)  14 -3.5 (-12,17)  5 -11 (-16,5)  
Tx=treatment week 24 (during treatment) ; BL=baseline (pre-treatment); F-up=Follow-up week 24 (post-treatment) 
*p-value corresponds to the Wilcoxon rank sum or Kruskal-Wallis test. 
R=6 month virological responders 
NR=6 month nonresponders 
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Table 6-9. Supplement 2a: Relative risk of dyslipidemia by selected predictors (1 of 2) 
Feature RR* (95%CI) p 
Demographics 
AA 0.96 (0.86,1.07) 0.50 
  AA X time– 0.63 
Age (years)** 1.05 (0.97,1.13) 0.22 
  Age X time– 0.48 
Male 1.23 (1.09,1.39) 0.001 
  Male X time– 0.58 
Health insurancea 0.97 
   Uninsured 1.01 (0.89,1.15) 0.86 
   Public 0.99 (0.87,1.13) 0.92 
     Insurance X time– 0.10 
Educational attainmentb  0.09 
   High school degree 0.91 (0.78,1.06) 0.22 
   Some college 0.89 (0.77,1.04) 0.14 
   >College degree 1.02 (0.89,1.18) 0.74 
     Education X time– 0.15 
Employed  1.05 (0.94,1.17) 0.37 
  Employed X time– 0.12 
Health risk behaviors 
Current smoker 1.09 (0.99,1.20) 0.09 
  Smoking X time– 0.26 
>2 Alcoholic drinks/week 0.88 (0.77,1.003) 0.06 
  Alcohol intake X time– 0.31 
General clinical features 
BMI*** 1.07 (1.02,1.12) 0.003 
  BMI X time– 0.92 
Waist to hip ratio^ 2.22 (1.41,3.48) 0.001 
  Waist to hip ratio X time– 0.56 
Diabetic 1.22 (1.09,1.37) <0.001 
  Diabetic X time– 0.66 
Hypertensive 1.03 (0.92,1.16) 0.57 
  Hypertensive X time– 0.96 
Transformations as noted: ^ = 1 – reciprocal 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 6 
month responder status. 
Reference group for regression models as follows: aPrivate insurance; bLess than high school degree 
**Per 10 unit increase; ***Per 5 unit increase 
–Not statistically significant (p>0.05) interaction terms not included in models.
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Table 6-10. Supplement 2b: Relative risk of dyslipidemia by selected predictors (2 of 2) 
Feature RR* (95%CI) p 
Viral characteristics   
Log10 HCV level  1.11 (1.03,1.19) 0.007 
  Viral level X time–  0.38 
HCV genotypea  0.02 
    1, NOS 1.02 (0.84,1.24) 0.86 
    1b 1.002 (0.90,1.12) 0.97 
    1a/b 1.20 (1.06,1.36) 0.003 
  HCV Genotype X time–  0.72 
Liver disease indicators   
ALT (IU/L)` 1.03 (0.95,1.11) 0.51 
  ALT X time–  0.67 
AST (IU/L)` 1.02 (0.92,1.12) 0.74 
  AST X time–  0.34 
Alk phosphatase (IU/L)` 1.11 (0.96,1.29) 0.15 
  Alk phosphatase X time–  0.46 
Total bilirubin (mg/dL)^ 1.03 (0.96,1.10) 0.45 
  Total bilirubin X time–  0.76 
INR   
  INR X time–  0.02 
WBC count (103/mL) 1.03 (1.01,1.05) 0.002 
  WBC X time–  0.72 
Platelet count (103/mL)*** 1.05 (0.98,1.13) 0.14 
  Platelet count X time–  0.11 
Ferritin (ng/mL)*** 1.001 (0.98,1.02) 0.89 
  Ferritin X time–  0.95 
Albumin (g/dL) 1.01 (0.87,1.18) 0.88 
  Albumin X time–  0.88 
%Iron/TIBC** 1.01 (0.99,1.02) 0.34 
  %Iron/TIBC X time–  0.88 
Ishak score 1.01 (0.98,1.04) 0.65 
  Ishak score X time–  0.11 
Ishak score > 3 1.03 (0.93,1.13) 0.63 
  Ishak score > 3Xtime–  0.88 
Fat score 1.08 (1.01,1.16) 0.02 
  Fat score X time–  0.37 
Steatosis (>5% present) 1.09 (0.98,1.22) 0.12 
  Steatosis X time–  0.63 
Total HAI inflammation^ 0.59 (0.34,1.03) 0.06 
  HAI inflammation X time–  0.08 
Iron scoreb  0.24 
   1 1.09 (0.98,1.21) 0.12 
   2 0.98 (0.80,1.19) 0.83 
  Iron score X time–  0.16 
Transformations as noted: ` = natural log; ^ = 1 – reciprocal 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 
6 month responder status. 
Reference group for regression models as follows: a1a genotype; b0 Iron score 
**Per 10 unit increase; ***Per 100 unit increase 
–Not statistically significant (p>0.05) interaction terms not included in models.   
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  Table 6-11. Supplement 3a: GEE models of each lipid profile measure by selected predictors (1 of 4) 
Feature ln(TG)  LDLc  ln(HDLc)  ln(TC)  
 β* (95%CI) p β* (95%CI) p β* (95%CI) p β* (95%CI) p 
Demographics        
AA -0.02 (-0.13,0.08) 0.67   0.04 (-0.02,0.11) 0.21   
  AA X time–  0.07  <0.001  0.97  <0.001 
Age (years)** 0.001 (-0.06,0.06) 0.99 2.1 (-2.5,6.8) 0.37 -0.01 (-0.06,0.03) 0.57   
   Age X time–  0.45  0.23  0.67  0.04 
Male 0.12 (0.02,0.22) 0.02 -6.6 (-14.7,1.5) 0.11 -0.22 (-0.29,0.15) <0.001 -0.07 (-0.11,-0.02) 0.007 
  Male X time–  0.37  0.58  0.31  0.84 
Health insurancea   0.41  0.78  0.25 
   Uninsured  -3.7 (-14.8,7.4) 0.52 0.02 (-0.07,0.11) 0.68 -0.04 (-0.11,0.03) 0.25 
   Public  -6.0 (-15.4,3.4) 0.21 -0.02 (-0.10,0.06) 0.64 -0.04 (-0.09,0.02) 0.17 
     Insurance X time–  0.007  0.72  0.68  0.85 
Educational attainmentb   0.59  0.10  0.30  0.08 
   High school degree -0.04 (-0.21,0.13) 0.63 -4.7 (-15.5,6.2) 0.40 0.02 (-0.08,0.12) 0.63 -0.02 (-0.09,0.05) 0.51 
   Some college -0.001 (-0.16,0.16) 0.99 -4.8 (-15.4,5.8) 0.38 0.08 (-0.02,0.18) 0.12 -0.01 (-0.07,-0.06) 0.78 
   >College degree 0.05 (-0.10,0.21) 0.50 6.9 (-5.0,18.9) 0.25 0.07 (-0.03,0.18) 0.16 0.06 (-0.01,0.13) 0.12 
     Education X time–  0.052  0.72  0.63  0.33 
Employed   3.7 (-4.2,11.6) 0.36 0.01 (-0.06,0.08) 0.79   
  Employed X time–  0.03  0.43  0.94  0.01 
Health risk behaviors        
Current smoker 0.11 (0.0002,0.21) 0.0496 1.3 (-6.7,9.3) 0.75 -0.05 (-0.12,0.01) 0.11 0.01 (-0.04,0.06) 0.70 
  Smoking X time–  0.18  0.22  0.06  0.25 
>2 Alcoholic drinks/week -0.08 (-0.20,0.03) 0.15 -0.6 (-9.5,8.2) 0.89 0.09 (0.01,0.17) 0.03 0.001 (-0.05,0.05) 0.97 
  Alcohol intake X time–  0.59  0.15  0.23  0.59 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 6 month responder status.  
Reference group for regression models as follows: aPrivate insurance; bLess than high school degree 
**Per 10 unit increase 
–Not statistically significant (p>0.05) interaction terms not included in models. 
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  Table 6-12. Supplement 3b: GEE models of each lipid profile measure by selected predictors (2 of 4) 
ln(TG)  LDLc  ln(HDLc)  ln(TC)  
Feature β* (95%CI) p β* (95%CI) p β* (95%CI) p β* (95%CI) p 
General clinical features         
BMI**   0.8 (-2.2,3.8) 0.60 -0.05 (-0.08,-0.02) <0.001 -0.001 (-0.02,0.02) 0.92 
  BMI X time–  0.03  0.43  0.84  0.45 
Waist to hip ratio (WHR)^   -7.8 (-38.7,23.0) 0.62 -0.65 (-0.93,-0.37) <0.001   
  WHR X time–  0.01  0.26  0.95  0.003 
Diabetic 0.12 (-0.05,0.29) 0.18 -2.0 (-15.2,11.1) 0.77 -0.16 (-0.26,-0.06) 0.002 -0.03 (-0.11,0.05) 0.40 
  Diabetic X time–  0.98  0.09  0.90  0.09 
Hypertensive   -3.1 (-11.0,4.9) 0.45 -0.10 (-0.17,0.03) 0.004 -0.03 (-0.08,0.02) 0.26 
  Hypertensive X time–  0.049  0.06  0.49  0.89 
Viral characteristics         
Log10 HCV level  0.08 (0.01,0.15) 0.02 2.5 (-2.6,7.7) 0.34 -0.02 (-0.06,0.02) 0.34 0.02 (-0.01,0.05) 0.21 
  Viral level X time–  0.77  0.30  0.88  0.22 
HCV genotypea      0.69  0.44 
    1, NOS     0.01 (-0.12,0.15) 0.84 0.07 (-0.03,0.17) 0.20 
    1a/1b     -0.10 (-0.27,0.07) 0.24 -0.04 (-0.14,0.05) 0.39 
    1b     -0.01 (-0.08,0.06) 0.85 0.01 (-0.04,0.06) 0.74 
  HCV Genotype X time–  0.0004  0.02  0.72  0.37 
NOTE: β coefficients represent unit difference for each continuous variable on the raw scale or on a transformed scale as noted: 
^ = 1 – reciprocal 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 6 month responder status.  
**Per 5 unit increase  
a1a genotype reference group 
–Not statistically significant (p>0.05) interaction terms not included in models. 
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Table 6-13. Supplement 3c: GEE models of each lipid profile measure by selected predictors (3 of 4) 
ln(TG)  LDLc  ln(HDLc)  ln(TC)  
Feature β* (95%CI) p β* (95%CI) p β* (95%CI) p β* (95%CI) p 
Liver disease indicators         
ALT (IU/L)` 0.02 (-0.06,0.10) 0.63 -1.5 (-7.0,3.9) 0.59 -0.04 (-0.09,0.01) 0.15 -0.02 (-0.05,0.01) 0.27 
  ALT X time–  0.40  0.88  0.89  0.90 
AST (IU/L)` 0.06 (-0.03,0.14) 0.23 -1.9 (-8.3,4.4) 0.55 -0.02 (-0.09,0.04) 0.45 -0.01 (-0.05,0.03) 0.51 
  AST X time–  0.22  0.88  0.92  0.93 
Alk phosphatase (IU/L)`   -2.6 (-13.4,8.2) 0.64 -0.10 (-0.21,0.0003) 0.051 -0.002 (-0.07,0.07) 0.95 
 Alk phosphatase X time–  0.003  0.73  0.57  0.53 
Total bilirubin (mg/dL)^ -0.02 (-0.06,0.03) 0.50 0.2 (-2.8,3.2) 0.88 -0.01 (-0.03,0.02) 0.48 -0.004 (-0.02,0.02) 0.73 
  Total bilirubin X time–  0.18  0.06  0.39  0.052 
INR -0.52 (-0.94,-0.11) 0.01 -2.1 (-35.7,31.5) 0.90 -0.05 (-0.31,0.20) 0.69   
  INR X time–  0.42  0.052  0.89  0.03 
WBC count (103/mL) 0.03 (0.01,0.06) 0.10   -0.03 (-0.05,-0.02) <0.001   
  WBC X time–  0.56  0.02  0.18  0.03 
Platelet count (103/mL)*** -0.01 (-0.08,0.06) 0.74 6.9 (1.6,12.2) 0.01 0.03 (-0.02,0.08) 0.21 0.05 (0.02,0.08) 0.003 
  Platelet count X time–  0.80  0.69  0.72  0.58 
Ferritin (ng/mL)***   -1.3 (-2.4,-0.2) 0.02 -0.01 (-0.02,0.003) 0.13 -0.01 (-0.01,0.0001) 0.052 
  Ferritin X time–  0.02  0.07  0.39  0.52 
Albumin (g/dL) 0.08 (-0.07,0.23) 0.31   -0.01 (-0.11,0.08) 0.78 0.01 (-0.06,0.08) 0.72 
  Albumin X time–  0.11  0.02  0.59  0.12 
%Iron/TIBC** 0.003 (-0.01,0.02) 0.65 -0.7 (-2.0,0.5) 0.25 -0.01 (-0.02,-0.01) 0.001 -0.01 (-0.01,0.002) 0.14 
  %Iron/TIBC X time–  0.69  0.23  0.16  0.44 
Transformations as noted: ` = natural log; ^ = 1 – reciprocal 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 6 month responder status. 
**Per 10 unit increase 
***Per 100 unit increase 
–Not statistically significant (p>0.05) interaction terms not included in models.  
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Table 6-14. Supplement 3d: GEE models of each lipid profile measure by selected predictors (4 of 4) 
ln(TG)  LDLc  ln(HDLc)  ln(TC)  
Feature β* (95%CI) p β* (95%CI) p β* (95%CI) p β* (95%CI) p 
Liver biopsy measures         
Ishak score   -1.7 (-4.1,0.7) 0.17 -0.03 (-0.05,-0.01) 0.02 -0.02 (-0.03,-0.005) 0.009 
  Ishak score X time–  0.02  0.86  0.26  0.59 
Ishak score > 3 -0.03 (-0.13,0.07) 0.52 -3.9 (-11.3,3.6) 0.31 -0.08 (-0.15,-0.01) 0.02 -0.05 (-0.09,-0.004) 0.03 
  Ishak score > 3Xtime–  0.10  0.60  0.76  0.60 
Fat score 0.18 (0.10,0.26) <0.001 -3.7 (-9.0,1.6) 0.18 -0.07 (-0.13,-0.01) 0.02 -0.01 (-0.04,0.03) 0.64 
  Fat scoreXtime–  0.14  0.78  0.90  0.60 
Steatosis (>5% present) 0.21 (0.11,0.31) <0.001 -7.9 (-15.6,-0.1) 0.046 -0.10 (-0.17,-0.03) 0.003 -0.03 (-0.08,0.01) 0.16 
  SteatosisXtime–  0.22  0.75  0.82  0.32 
Total HAI inflammation^ 0.16 (-0.79,1.12) 0.74 -68.6 (-126.7,-10.4) 0.02 -0.23 (-0.72,0.27) 0.37 -0.43 (-0.76,-0.09) 0.01 
  HAI inflammation X 
time– 
 0.47  0.37  0.39  0.45 
Iron score*    0.60  0.19  0.50 
   1   -1.4 (-9.8,6.9) 0.74 -0.07 (-0.14,0.01) 0.07 -0.03 (-0.08,0.02) 0.30 
   2   -5.7 (-20.6,9.1) 0.45 -0.05 (-0.17,0.08) 0.45 -0.03 (-0.12,0.05) 0.41 
   Iron score X time–  0.002  0.53  0.08  0.28 
^ = 1 – reciprocal transformation 
*Adjusting for race, the proportion of PEG-IFN taken between time points (time dependent covariate), time, and 6 month responder status. 
*0 Iron score reference group 
–Not statistically significant (p>0.05) interaction terms not included in models.  
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6.7 FIGURES 
 
Figure 6-1. Serum lipid profile changes during and after antiviral therapy 
* p<0.05;* * p<0.0001 (Wilcoxon signed rank test for differences from zero) 
Tx=assessment at treatment week 24 
F-up=assessment 24 weeks after stopping therapy  
R=Among treatment week 24 virological responders (underwent a 48 week course of therapy) at week 72 
NR=Among treatment week 24 virological nonresponders (underwent a 24 week course of therapy) at week 48 
NOTE: Boxplots exclude extreme outliers for changes in TG levels: -768, -422, 477, 477, 562, 573, 629, and 1678 
mg/dL on treatment; 434 mg/dL during follow-up among 6 month virological responders. Baseline median levels as 
follows: 100 mg/dL (TG); 115.5 mg/dL (LDLc); 41.1 (HLDc); and 183 (TC).    
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Figure 6-2. The amount of PEG-IFN taken and serum lipid profile changes during therapy 
p corresponds to test of trend for lipid profile measures with the amount of PEG-IFN taken. Trend test for changes in 
TG, HDLc, and TC was on the natural log scale.  
NOTE: Difference in lipid profile measures at treatment week 24 minus baseline 
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Figure 6-3. Race and serum lipid profile changes during therapy 
*Wilcoxon test for racial differences 
NOTE: Difference in lipid profile measures at treatment week 24 minus baseline 
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7.0  PROJECT 3: ASSOCIATIONS BETWEEN THE SERUM LIPID PROFILE AND 
HEPATITIS C ANTIVIRAL TREATMENT EFFICACY 
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7.1 ABSTRACT 
BACKGROUND: Approximately one half of patients who undergo antiviral therapy for chronic 
HCV genotype 1 infection will not respond to treatment. In addition, African Americans (AAs) 
are less responsive to treatment than Caucasian Americans (CAs) and reasons for this disparity 
are unknown. Several recent studies suggest that pretreatment lipid profile measures are 
predictive of virological response to therapy. AIMS: To evaluate if lipid profile measures are 
predictive of virological response and to evaluate if these measures explain the racial difference 
in efficacy. METHODS: Participants were from Virahep-C, a prospective study of treatment 
naïve participants who received combination therapy of PEG-IFN alfa-2a + ribavirin for up to 48 
weeks. Pretreatment fasting lipid profiles were analyzed for 160 AAs and 170 CAs. A relative 
risk (RR) model was employed to evaluate characteristics associated with sustained virological 
response (SVR) defined as undetectable HCV RNA 24 weeks after the cessation of therapy. 
Baseline patient histological, virological, demographic, and clinical variables were eligible for 
entry in multivariable modeling, in addition to the amount of PEG-IFN taken and body weight 
changes during the first 24 weeks of therapy. RESULTS: In univariable assessments, 
triglyceride (TG) and low density lipoprotein cholesterol (LDLc) were associated with SVR. In 
multivariable modeling, factors associated with a higher rate of SVR included CA race, the 
amount of PEG-IFN taken, and LDLc. In contrast, male gender, high HCV viral level, Ishak 
fibrosis score, and TG were associated with lower rates of SVR. Significant interactions were 
also detected between baseline viral level and race and between high density lipoprotein 
cholesterol (HDLc) and gender. The final area under the receiver operator curve was 0.811 and 
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did not significantly improve the prediction of SVR compared to a more parsimonious, 
previously published model (p=0.44). CONCLUSIONS: TG, LDLc, and the interaction of 
HDLc and gender were significantly associated with SVR in addition to other previously 
identified factors. The lipid parameters did not explain the racial difference in treatment 
response. These findings are compatible with proposed biological mechanisms of HCV entry, 
replication, and secretion, and underscore new potential therapeutic targets for HCV eradication. 
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7.2 INTRODUCTION 
In the United States (US), chronic HCV infection is a major public health problem afflicting 3.6 
million persons with direct health care costs, including liver transplantation, exceeding $1 billion 
dollars annually.3, 74 The current standard treatment, combination PEG-IFN alfa-2a and ribavirin, 
is less effective in genotype 1 (the predominate viral type in the US) with approximately 46% 
people achieving sustained virological response (SVR) compared to other genotypes.8 Moreover, 
in the US, genotype 1 virological response is characterized by a racial differences as African 
Americans (AAs) are significantly less responsive than Caucasian Americans (CAs).10-12 Factors 
that explain the racial disparity in efficacy are unknown.10 
Recent studies suggest that pretreatment lipid profile measures may be important 
predictors of treatment response. Several studies indicate that high pretreatment low density 
lipoprotein cholesterol (LDLc) and total cholesterol (TC) levels are associated with higher rates 
of SVR in multivariable analyses.61-65 In addition, pretreatment triglyceride (TG) levels have 
been found to be higher among virological responders compared to non-responders.52 These 
studies also suggest that associations between lipid profile measures and virological response 
may be specific to HCV genotype 1 and possibly genotype 2. 
The observations from epidemiologic studies reflect work from in vitro evaluations that 
relate lipoproteins and HCV to mechanisms of viral entry into hepatocytes from the serum, 
replication, and secretion. Several studies suggest that HCV may complex with lipoproteins in 
the serum, possibly masking the virus from the host immune response.30-33 Various receptors 
involved in lipoprotein-viral particle entry into hepatocytes are posited, including the scavenger 
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receptor B1 (SR-B1) and LDL receptor.34-37 Direct entry of free HCV (i.e., not associated with 
lipoproteins) is also proposed to occur through binding with SR-B1 or CD81.40-42 Within the 
hepatocyte endoplasmic reticulum, studies support HCV replication being reliant on cholesterol 
metabolism and a process of HCV secretion with very low density lipoprotein (VLDL) as 
complexed particles.29, 43-46 Recent work suggests that SR-B1 may play a role in the mechanism 
of antiviral therapy with down-regulation of SR-B1 expression, the lipoprotein receptor which 
mediates removal of high density lipoprotein from the serum, following exposure to interferon 
alfa.72 This supports the notion that down regulation may impact serum lipoprotein and lipid 
profile measures. 
Associations between the serum lipid profile and treatment response are supported by 
biologically plausible mechanisms. This study assesses relationships between measures of the 
lipid profile, both pretreatment and on-treatment changes, and virological response in a cohort of 
participants with chronic HCV genotype 1 infection. In addition, this study evaluates if lipid 
profile measures account for any of the racial difference in treatment efficacy. 
7.3 METHODS 
7.3.1 Study population 
Participants for this study were from the Virahep-C study, an investigation of resistance to 
antiviral therapy for chronic HCV infection, genotype 1. This study has been described 
elsewhere.10 In brief, Virahep-C sought to evaluate clinical, immunological, virological, and host 
genetic factors that contribute to the lack of virological response to antiviral treatment, and in 
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particular, the racial difference in efficacy. The study enrolled approximately equal numbers of 
Caucasian Americans (CA) (n=205) and African Americans (AA) (n=196), all of whom 
underwent a combination PEG-IFN alfa-2a and ribavirin regimen for up to 48 weeks. At 24 
weeks of therapy, participants were evaluated for the presence of HCV RNA and those with 
detectable levels discontinued therapy and entered follow-up, whereas the others continued 
therapy for an additional 24 weeks.  
Funding for lipid profile analyses utilizing stored fasting serum samples was obtained for 
an ancillary study to examine relationships between host genetic polymorphisms, the lipid 
profile, and steatosis (KL2 RR024154-02 to LJY). Of the 401 participants enrolled in Virahep-C, 
lipid profile analyses were conducted among participants who granted genetic consent (n=374) 
and had stored fasting serum samples at baseline (n=335). The five participants who reported use 
of lipid lowering medications were excluded from this evaluation resulting in a final analysis 
sample of 330 participants (170 CA and 160 AA). During treatment (24 weeks after starting 
therapy) and post-treatment (24 weeks after stopping therapy) lipid profile data were available 
for 253 and 245 of the participants, respectively.  
 
7.3.2 Study measures 
The primary outcome for Virahep-C was sustained virological response (SVR), defined as 
undetectable serum HCV RNA 24 weeks after the end of therapy. The lipid profile measures, 
TG, LDLc, high density lipoprotein cholesterol (HDLc), and TC, were obtained through analysis 
of stored fasting serum samples at the Heinz Nutrition Laboratory in the Department of 
Epidemiology, University of Pittsburgh. For serum samples with TG levels less than 400 mg/dL, 
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the Friedewald formula was used to calculate LDLc indirectly (LDLc = TC − HDLc − 0.20 X 
TG).28 For samples with TG levels of at least 400 mg/dL, LDLc was assessed directly. 
Inflammation and fibrosis were assessed using the criteria of the Histological Activity Index 
(HAI) by a single hepatopathologist.19, 20 The amount of PEG-IFN and ribavirin taken by 
participants was estimated using data from the Medication Event Management System (MEMS) 
(Aardex, Zug, Switzerland).73 
7.3.3 Statistical analysis 
To evaluate factors associated with SVR, a relative risk model was employed with a robust 
variance estimator.71. For all statistical tests, a p-value of <0.05 was considered statistically 
significant. All continuous predictors were centered. The relationships between baseline and 24 
week changes during treatment in lipid profile measures and the probability of SVR were 
graphically assessed using smoothing spline plots. Two types of multivariable models of 
sustained virological response were constructed using a stepwise approach. One type of 
multivariable model (models 1 and 2) allowed pretreatment characteristics and the amount of 
PEG-IFN alfa-2a taken during the first 24 weeks as eligible predictors. Model 2 allowed as 
eligible predictors baseline lipid profile measures. A second type of multivariable model (model 
3) also adjusted for body weight changes and allowed variables representing baseline and 
changes in lipid profile measures during the first 24 weeks of therapy as eligible predictors. To 
compare the prediction of multivariable models, differences in the area under the receiver 
operating curves (AUROCs) were assessed using a non-parametric method.75 
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7.4 RESULTS 
Characteristics of the 330 participants are shown in Tables 5-1 and 5-2 on pages 31–32 and 
described on page 24.  
Characteristics associated with SVR are summarized in Table 7-1. Features significantly 
associated with higher SVR included CA race (RR=1.92, p<0.001, AA reference) and education 
beyond high school (RR=0.64, p=0.002, less than high school degree reference). Features 
inversely related to SVR included body weight (RR=0.95 per 5 kg increase, p=0.01), baseline 
log10 HCV level (RR=0.77, p<0.001), and fibrosis (Ishak) score (RR=0.90, p=0.02), whereas 
platelet count (RR=1.25 per 103 cells/mm3 increase, p=0.01) and the amounts of PEG-IFN 
(RR=1.41 per 10% increase, p<0.001) and ribavirin (RR=1.25  per 10% increase, p<0.001) taken 
during the first 24 weeks of therapy were directly related to the rate of SVR. Baseline natural log 
of TG (RR=0.65, p=0.002) and LDLc (RR=1.05 per 10 mg/dL increase, p=0.002) were inversely 
and directly related to the rate of SVR, respectively. The natural logs of baseline HDLc and TC 
levels were not significantly associated with SVR.  
In crude and race-adjusted regression models, the relationships between variables 
representing the changes in lipid profile measures (both during and after therapy) and the rate of 
SVR are summarized in Table 7-2. SVR rates were directly associated with increases and 
declines in the natural log of TG (RRcrude=1.43, p=0.001; RRadjusted=1.29, p=0.02) and LDLc 
(RRcrude=0.96, p<0.001; RRadjusted=0.97, p=0.02, per 5 mg/dL increase) during 24 weeks of 
therapy, respectively, compared to pretreatment. Post-treatment values, and increases in both 
LDLc (RRcrude=1.04, p=0.001; RRadjusted=1.04, p=0.001, per 5 mg/dL increase) and the natural 
log of TC (RRcrude=4.64, p<0.001; RRadjusted=4.10, p<0.001) from baseline were directly related 
to the rate of SVR.  
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Assessed graphically in smoothing spline plots, relationships between the probability of 
SVR and baseline and changes in TG, LDLc, TC, and HDLc (by gender) during 24 weeks of 
therapy are displayed Figures 7-1 to 7-5. The natural logs of baseline TG and increases in TG 
during therapy were inversely and directly related to the probability of SVR, respectively. 
Baseline LDLc and declines in LDLc from baseline during 24 weeks of therapy were directly 
related to the probability of SVR. Although not statistically significant in regression models 
(Tables 7-1 and 7-2), baseline and on-treatment changes in the natural log of TC showed a 
similar relationship to SVR as LDLc. In males, the natural log of HDLc was inversely related to 
SVR rates, while in females the relationship was opposite.  
The multivariable model reported by Conjeevaram et al. based on 400 participants was fit 
for the 329 participants for whom lipid profile and covariate data were available.10 (Table 7-3: 
model 1) In model 1, factors significantly associated with SVR included CA race (RR=1.98, 
p<0.001), male gender (RR=0.80, p=0.049), baseline viral level (RR=0.57, p=<0.001 per log10 
increase), Ishak fibrosis score (RR=0.90, p=0.009), and the amount of PEG-IFN taken during the 
first 24 weeks (RR=1.38, p<0.001 per 10% dose increase). In addition, there was a significant 
interaction between race and baseline viral level (p=0.005), indicating that the magnitude of the 
inverse relationship between viral level and the rate of SVR differed by race, (RR=0.86, p=0.03 
for CAs, RR=0.57, p<0.001 for AAs). Using the same eligible predictors as model 1 and 
allowing the baseline lipid profile variables to be eligible for entry, model 2 was created. In 
model 2, a significant interaction between HDLc and gender (p=0.02) with SVR was found 
indicating that the inverse relationship between HDLc and the rate of SVR decreased 66% 
(p=0.006) per 1 unit natural log increase of HDLc among males, whereas no significant 
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relationship was found among females. The prediction of SVR did not significantly differ 
between the models 1 and 2 (AUROCs=0.801 vs 0.811, respectively, p=0.42). (Figure 7-6)  
In multivariable modeling, model 3 was constructed using 250 participants who had 
covariate, baseline lipid profile, and treatment week 24 lipid profile data. (Table 7-3) Model 3 
evaluated the relationships between lipid profile changes during therapy as predictors of SVR, in 
addition to other variables eligible for entry into models 1 and 2. Variables included in models 2 
and 3 were similar, though the baseline natural log of TG and LDLc levels were not included in 
model 3, but the change in LDLc during the first 24 weeks was retained. The AUROC for model 
3 was not significantly different than that of model 1 fit to the same 250 participants 
(AUROC=0.799 vs 0.779, p=0.19). (Figure 7-7) In contrast to model 2, in model 3 the 
significant interaction (p=0.009) between the natural log of HDLc and the rate of SVR indicated 
a direct relationship (RR=2.15, p=0.008) among females, but not males (p=0.35), a possible 
reflection of the smaller subset upon which model 3 was fit. In all three multivariable models, 
race remained a significant predictor of SVR and the strength of the association was little 
changed by the addition of the lipid profile measures.   
7.5 DISCUSSION 
This evaluation of the lipid profile and virological response showed that pretreatment TG and 
LDLc levels were inversely and directly related to the rate of SVR, respectively. Furthermore, 
changes in these two parameters during the first 24 weeks of therapy were associated with 
virologic response with larger increases in TG and larger declines in LDLc associated with 
higher rates of SVR. In multivariable modeling, several lipid profile parameters (baseline TG, 
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LDLc, HDLc, and TG, and LDLc changes during treatment) were significant predictors of SVR. 
However, including the lipid profile measures did not significantly improve the prediction of 
SVR compared to models without these measures, nor did lipid profile measures account for the 
racial difference in treatment efficacy between CAs and AAs.  
The direct relationship between pretreatment LDLc levels and the rate of SVR is 
consistent with findings from several other studies.61-65 Other work 52 has reported an association 
between higher pretreatment TG levels and virologic response, opposite of the relationship in the 
current study, possibly a reflection of the HCV genotype distributions. In this study only people 
infected with HCV genotype 1 were included, whereas the predominant genotype represented in 
the previously referenced study was genotype 2. In multivariable analyses, significant 
interactions between HDLc levels and gender in relation to virologic response were found, which 
have not been previously reported. These relationships warrant further investigation and 
validation in other cohorts to clarify if lipid profile measures are important predictors of 
treatment response. Post-therapy, increases from baseline in LDLc and TC were found to be 
associated with SVR, which may correspond to HCV eradication and the subsequent resolution 
of HCV-induced liver damage.  
With evidence from in vitro work supporting several possible mechanisms involving 
serum lipoproteins, cholesterol metabolism, lipoprotein receptors, and the replication and 
secretion of HCV, the significant relationships between both baseline and changes from baseline 
LDLc and TG levels and rates of SVR are biologically feasible.29-37, 43-46 The direct relationship 
between LDLc and SVR may partially be explained by competition for LDL receptor sites 
preventing viral entry into hepatocytes, increasing exposure to the host immune response in the 
serum. These findings suggest that the lipid profile may yield some prognostic value in 
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determining the probability of treatment success and possibly highlight new therapeutic targets. 
Further prospective investigation of the impacts of dietary modification and lipid lowering agents 
on virological response is warranted. Treatment trials investigating statins and fibrates to 
improve virological response have yielded mixed results.13, 76, 77  
This study suggests that lipid profile measures are predictors of SVR, but that these 
measures do not explain the racial disparity in treatment efficacy between CAs and AAs. 
Accounting for other predictors of virologic response, incorporating lipid profile variables did 
not yield a significant improvement in the prediction of SVR compared to another more 
parsimonious model. However, this study underscores the potential relevance of the serum lipid 
profile in virologic response and further research is warranted to investigate the relationships 
between other characterizations of the lipid profile, genetic determinates of lipid metabolism, and 
SVR.  
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7.6 TABLES 
  Table 7-1.  Univariable models of SVR and selected predictors in the lipid profile assessment subset 
Feature RR (95%CI) p 
CA Race 1.92 (1.45,2.56) <0.001 
Male gender 0.79 (0.61,1.02) 0.07 
Age† 0.96 (0.89,1.04) 0.31 
Years infected 1.005 (0.99,1.02) 0.54 
< High school education 0.64 (0.48,0.85) 0.002 
Weight (kg) † 0.95 (0.91,0.99) 0.01 
BMI (kg/m2) 0.98 (0.96,1.01) 0.23 
History of diabetes 0.52 (0.27,1.01) 0.054 
History of hypertension 0.76 (0.56,1.04) 0.09 
Antidepressant drug use 0.60 (0.18,2.00) 0.40 
Current alcohol use 0.92 (0.66,1.27) 0.60 
Current smoker 1.10 (0.85,1.43) 0.48 
ALT (IU/L) # 1.09 (0.94,1.25) 0.26 
ALT (IU/L)** 1.08 (0.90,1.31) 0.40 
AST (IU/L) # 0.83 (0.61,1.10) 0.18 
AST (IU/L)** 0.83 (0.66,1.04) 0.11 
INR 1.43 (0.48,4.26) 0.52 
Hemoglobin (g/dL) 0.95 (0.86,1.05) 0.30 
White blood cells  (per 103 cells/mm3) 1.05 (0.99,1.11) 0.12 
Platelet count (per 105 cells/mm3)  1.25 (1.06,1.49) 0.01 
Genotype 1a vs. non-1a 0.88 (0.68,1.13) 0.32 
Baseline viral level (IU)* 0.77 (0.66,0.89) <0.001 
Ishak fibrosis score 0.90 (0.82,0.98) 0.02 
Ishak fibrosis score > 3 0.82 (0.62,1.08) 0.16 
Cirrhosis (Fibrosis score 5–6) 0.65 (0.34,1.24) 0.20 
Steatosis score 0.85 (0.67,1.07) 0.17 
Steatosis (>5% present) 0.86 (0.66,1.11) 0.24 
HAI inflammation score 0.995 (0.95,1.05) 0.85 
Proportion of peg-IFN taken` 1.41 (1.18,1.68) <0.001 
Proportion of ribavirin taken` 1.25 (1.15,1.35) <0.001 
Lipid parameters:***   
TG** (mg/dL) 0.65 (0.49,0.86) 0.002 
LDLc^ (mg/dL) 1.05 (1.02,1.09) 0.002 
HDLc* (mg/dL) 0.96 (0.64,1.44) 0.84 
TC* (mg/dL) 1.59 (0.84,3.01) 0.15 
Transfomations as noted: *Log10 transformed; **Natural log transformed 
Relative risk: †per 5 unit increase; ^per 10 unit increase; #per 100 unit increase; `per 10% increase in dose 
***Eligible for entry in multivariable model 2
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     Table 7-2. Evaluation of lipid profile measure changes during and after therapy as predictors of SVR 
SVR 
Unadjusted Race-adjusted 
Lipid profile measure RR (95%CI) p RR (95%CI) p 
Δ: On Tx – Baseline n=253  n=253  
TG* (mg/dL) 1.43 (1.15,1.78) 0.001 1.29 (1.05,1.59) 0.02 
LDLc† (mg/dL) 0.96 (0.92,0.98) <0.001 0.97 (0.95,0.995) 0.02 
HDLc* (mg/dL) 1.13 (0.63,2.02) 0.68 1.13 (0.65,1.96) 0.66 
TC* (mg/dL) 0.49 (0.23,1.08) 0.08 0.64 (0.30,1.35) 0.24 
Δ: F-up – Baseline n=245  n=245  
TG* (mg/dL) 1.29 (0.98,1.70) 0.07 1.24 (0.97,1.61) 0.09 
LDLc† (mg/dL) 1.04 (1.02,1.06) 0.001 1.04 (1.01,1.06) 0.001 
HDLc* (mg/dL) 0.94 (0.54,1.66) 0.84 0.92 (0.54,1.58) 0.78 
TC* (mg/dL) 4.64 (2.46,8.76) <0.001 4.10 (2.14,7.85) <0.001 
  *Natural log transformed  
  †per 5 mg/dL change 
 
 
 
 
 
 
 
 
  89
   Table 7-3.  Multivariable models of SVR and selected predictors 
Model 1 Model 2 Model 3 
Feature RR (95%CI) p RR (95%CI) p RR (95%CI) p 
CA Race 1.98 (1.47,2.67) <0.001 1.81 (1.33,2.45) <0.001 2.28 (1.58,3.30) <0.001 
Male gender 0.80 (0.64,0.999) 0.049 0.81 (0.62,1.07) 0.14 0.96 (0.72,1.27) 0.76 
Baseline viral level (IU)* 0.57 (0.44,0.73) <0.001 0.58 (0.45,0.75) <0.001 0.47 (0.34,0.63) <0.001 
Baseline viral level (IU)* and 
race interaction  0.005  0.006  0.001 
      CA 0.86 (0.75,0.98) 0.03 0.87 (0.75,0.997) 0.045 0.80 (0.69,0.93) 0.004 
      AA 0.57 (0.44,0.73) <0.001 0.58 (0.45,0.75) <0.001 0.47 (0.34,0.63) <0.001 
Ishak fibrosis score 0.90 (0.83,0.97) 0.009 0.91 (0.83,0.98) 0.02 0.90 (0.83,0.98) 0.02 
Amount of peg-IFN taken` 1.38 (1.18,1.62) <0.001 1.37 (1.18,1.60) <0.001 0.98 (0.85,1.12) 0.77 
Lipid parameters:***       
TG** (mg/dL)   0.69 (0.52,0.91) 0.009   
HDLc** (mg/dL)   NA NA NA NA 
HDLc** (mg/dL) and gender 
interaction 
   0.02  0.009 
    Male   0.44 (0.25,0.79) 0.006 0.76 (0.43,1.35) 0.35 
    Female   1.10 (0.60,2.02) 0.75 2.15 (1.22,3.78) 0.008 
LDLc^ (mg/dL)   1.03 (1.001,1.07) 0.046   
ΔLDLc^ (mg/dL)     0.97 (0.95,0.996) 0.02 
Model 1=Replication of Conjeevaram et al. model 9 on subset of participants with available baseline lipid profile data (n=330)  
Model 2=Baseline lipid profile variables as eligible for entry 
Model 3=Multivariable model with baseline and on treatment changes from baseline in lipid profile variables as eligible for entry (n=253). Model also adjusts for changes in 
body weight (not shown). 
Transformations as follows:  *Log10 transformed; **Natural log transformed 
RR estimate adjustment as follows:  ^per 5 unit increase; `per 10% increase in dose 
NA=Not applicable due to significant interaction with gender (refer to gender specific coefficients)  
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7.7 FIGURES 
 
 
 
Figure 7-1.  Baseline and changes in the natural log (ln) of TG during 24 weeks of therapy and the probability 
of SVR 
*Number of participants within interval for changes in ln(TG) from baseline 
**Number of participants within interval for baseline ln(TG)  
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Figure 7-2. Baseline and changes in LDLc during 24 weeks of therapy and the probability of SVR  
*Number of participants within interval for changes in LDLc from baseline 
**Number of participants within interval for baseline LDLc  
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 Figure 7-3. Baseline and changes in the natural log (ln) of TC during 24 weeks of therapy and the probability 
of SVR 
*Number of participants within interval for changes in ln(TC) from baseline 
**Number of participants within interval for baseline ln(TC)  
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 Figure 7-4. Baseline and changes in the natural log (ln) of HDLc during 24 weeks of therapy and the 
probability of SVR among males 
*Number of males within interval for changes in ln(HDLc) from baseline 
**Number of males within interval for baseline ln(HDLc)  
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 Figure 7-5. Baseline and changes in the natural log (ln) of HDLc during 24 weeks of therapy and the 
probability of SVR among females 
*Number of females within interval for changes in ln(HDLc) from baseline 
**Number of females within interval for baseline ln(HDLc)  
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 p=0.42 
Figure 7-6. Receiver operator curves of multivariable models 1 and 2 (n=329) 
AUROC=area under the receiver operator curve 
Model 1=Includes race, gender, baseline viral level, baseline viral level and race interaction, Ishak fibrosis score, 
and the amount of PEG-IFN taken  
Model 2=Includes variables in model 1, plus baseline TG, baseline HDLc, baseline HDLc and gender interaction, 
and baseline LDLc 
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 p=0.19 
Figure 7-7. Receiver operator curves of multivariable Models 1 and 3 
AUROC=area under the receiver operator curve 
Model 1=Includes race, gender, baseline viral level, baseline viral level and race interaction, Ishak fibrosis score, 
and the amount of PEG-IFN taken  
Model 2=Includes variables in model 1, body weight change, baseline HDLc, baseline HDLc and gender interaction, 
and the change in LDLc during 24 weeks of therapy 
  97
8.0  GENERAL DISCUSSION 
The three epidemiologic projects of this dissertation investigated different aspects of the serum 
lipid profile in the context of chronic HCV genotype 1 infection. Sharing this theme, the studies 
evaluated associations between the lipid profile measures and liver disease and viral 
characteristics prior to the initiation of treatment, characterized changes in the lipid profile 
measures during and after therapy, and assessed the relationships between lipid profile measures 
and treatment efficacy. The three projects revealed several new findings which underscore the 
relevance of the serum lipid profile in HCV infection, treatment, and treatment efficacy. The first 
project found significant associations between the serum lipid profile and several aspects of liver 
histology and a direct relationship between TG and HCV viral levels. The second project 
revealed significant changes in all aspects of the lipid profile during the first 24 weeks of 
therapy. For some components of the lipid profile, changes also significantly differed by race and 
were related to the amount of PEG-IFN taken. Lastly, the third project found that baseline LDLc, 
HDLc, and TG levels were significant predictors of treatment efficacy, as were changes in LDLc 
and TG levels during the first 24 weeks of therapy.  However, when lipid profile measures were 
considered along with other available data collected as part of the Virahep-C study, the racial 
disparity in treatment efficacy between AAs and CAs remained.  
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8.1 STRENGTHS AND LIMITATIONS 
The primary aim of the Virahep-C study was to examine factors involved in the racial difference 
in response to antiviral therapy between AAs and CAs. Accordingly, the study enrolled 
approximately equal numbers from each race group. One limitation, however, was that the cohort 
was two-thirds male, which limited the ability to assess gender or race/gender relationships with 
the lipid profile or treatment response. This limitation was further complicated since AA females 
had significantly larger BMIs and weights, both inversely associated with treatment response. 
Despite the sample size limitations, the three projects found that gender was associated with TG, 
HDLc, and TC, and males were less responsive to therapy than females. In the third project of 
treatment efficacy, there was a significant interaction between gender and HDLc with respect to 
the relationship with SVR.  
 Another limitation of the Virahep-C cohort is the highly selected population, which is 
likely not comparable to the general US population of chronic HCV infected people and limits 
the generalizability of the findings to other groups with more advanced liver disease. In addition, 
the study cohort was only infected with genotype 1, which precluded the ability to examine the 
lipid profile across HCV genotypes. The use of other sampling strategies would enhance the 
representativeness of the cohort to reflect the US population of people chronically infected with 
HCV. 
 Stepwise variable selection was used in multivariable modeling for all three projects, 
which has limitations. Based on statistical significance, predictors are selected out of subsets of 
variables for inclusion or exclusion into the model. Given two or more predictors significantly 
associated with an outcome, automated statistical software programs select those variables that 
remain significantly associated with the outcome in the presence of other significant variables, 
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making it possible that more biologically or clinically plausible variables may be excluded. In 
light of these limitations, two committee members assessed the biological (RWE) and clinical 
(HSC) relevance and plausibility of multivariable models.  
The cross-sectional project 1 has several inherent limitations. First, since the study 
examined associations between the lipid profile and liver disease measures, it is not possible to 
assess the direction of these relationships. For example, it is possible that either severe fibrosis or 
liver fat may have resulted in the observed patterns of the lipid profile, or visa versa. Another 
limitation of the first project is a result of the lack of a non-HCV exposed control group. Host 
factors resulting in certain types of chronic liver disease could not be disentangled from the 
contribution of chronic infection.  
This research is the first to characterize the serum lipid profile in a cohort of chronically 
infected people with HCV genotype 1 that includes a large proportion AAs, which afforded an 
opportunity to assess the role the role of race. In addition, this was the first study to characterize 
changes in the lipid profile during therapy in association with many other measures such as the 
amounts of drug taken and liver disease.  
8.2 FUTURE RESEARCH 
8.2.1.1  Additional lipid profile studies  
Per the original Virahep-C study design, fasting serum samples were collected and stored prior to 
treatment, 6 months after therapy began, and 6 months after stopping therapy. In addition, among 
6 month virological responders, fasting serum samples were collected at 48 weeks of therapy. 
With additional funding, further research may be able to assess if changes in the lipid profile 
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measures between 24 and 48 weeks of therapy predict virological breakthrough (n=17 in 
Virahep-C), defined as undetectable HCV RNA at 6 months of therapy and detectable levels at 
the end of treatment, which would further clarify the biological relevance of lipid profile 
measures in treatment induced viral eradication. However, the small sample size limits the power 
to evaluate relationships between breakthrough and lipid profile in the Virahep-C cohort.   
The relationship between HCV viral kinetics and changes in the serum lipid profile 
during treatment may also warrant further investigation. This evaluation would require more 
frequent assessments of the lipid profile during the first 28 days of therapy than were available in 
the Virahep-C study. Findings from this type of analysis would clarify if viral eradication occurs 
before, after, or in concert with lipid profile measure changes.  
8.2.2 Lipid profile sub-fraction and genetic studies 
The lipid profile measures examined in this investigation may be related to other factors involved 
in the racial difference in treatment response. Work to further characterize lipoprotein number 
and size using nuclear magnetic resonance imaging spectroscopy (NMR LipoProfile®) would 
yield more specific measures in the evaluation of treatment efficacy. Likewise, the genetic 
aspects of lipoprotein and cholesterol metabolism may be involved in virological response. 
These factors may warrant further study using stored samples from Virahep-C or other studies.  
8.2.3 Assessments of the role of diet and lipid altering medications 
PEG-IFN therapy is associated with numerous side-effects including gastrointestinal 
disturbances, such as nausea, weight loss, and anorexia9, and the impact of therapy on changes in 
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dietary intake as it relates to treatment response has not been well studied. In vitro work suggests 
that certain nutrients (i.e., beta-carotene, vitamin D2, and linoleic acid) may have inhibitory 
effects on HCV replication, both with and without combination antiviral therapy.78 Other work 
has focused on modifying cholesterol metabolism to inhibit HCV replication using lipid lowering 
agents, such as statins and fibrates, and have yielded mixed results with respect to viral kinetics 
and virological response.13, 76, 77 Prospective studies may be designed to further characterize these 
relationships and assess if intervention studies are warranted.  
8.2.4 Repeated measures of liver disease studies 
Project 3 identified significant post-treatment increases in LDLc, TG, and TC above pretreatment 
levels among sustained virological responders. These findings suggest that eradication of HCV 
may correspond with recovery from liver disease and subsequent increases in lipoprotein 
production. In addition, it is unclear if the changes observed over the course of therapy 
(described in Project 2) are associated with changes in liver disease. To assess these 
relationships, future studies may incorporate repeated liver disease measures from ultrasound 
imaging techniques as an alternative or in addition to invasive liver biopsies.  
8.2.5 Assessment of cardiovascular disease in chronic HCV 
Based on the relevance of the serum lipid profile to biological mechanisms of chronic HCV, this 
dissertation project focused primarily on each aspect of lipid profile as mutually exclusive 
measures. Although this was the main aim, the lipid profile measures were combined to create a 
composite outcome of dyslipidemia, a cardiovascular disease (CVD) risk factor as a secondary 
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focus. Several other measures of CVD, not available in the Virahep-C study, including pulse 
wave velocity assessments, inflammatory markers (such as C-reactive protein), carotid intima-
media thickness, or coronary calcification would afford an opportunity to examine CVD risk and 
associations with chronic HCV. Comparisons to an age-, gender-, and race- matched non-HCV 
exposed control group would suggest if CVD risk differs by infection status. In addition, in 
chronic HCV infected groups, repeated measures of these additional CVD indicators would 
allow assessments of changes in CVD risk in relation to virological response and treatment 
duration. 
 
8.3 PUBLIC HEALTH SIGNIFICANCE OF THIS RESEARCH 
This dissertation contributes to the understanding of the relationship between the lipid profile to 
potential biological mechanisms of HCV and is reflective of findings from in vitro work. In 
addition, the investigation highlights the relevance of the lipid profile in chronic HCV and 
suggests that lipid metabolism may play a role in predicting treatment efficacy. These 
contributions may influence future studies in the examination of new therapeutic targets and 
interventions to improve treatment response, decrease the health care costs associated, reduce the 
transmission of disease, prevent or slow the progression of chronic liver disease, and improve the 
quality of life of those with chronic HCV infection.  
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